+

US20080058423A1 - Melanin concentrating hormone antagonists - Google Patents

Melanin concentrating hormone antagonists Download PDF

Info

Publication number
US20080058423A1
US20080058423A1 US11/978,434 US97843407A US2008058423A1 US 20080058423 A1 US20080058423 A1 US 20080058423A1 US 97843407 A US97843407 A US 97843407A US 2008058423 A1 US2008058423 A1 US 2008058423A1
Authority
US
United States
Prior art keywords
biphenyl
ylmethyl
naphthalen
carboxylic acid
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/978,434
Inventor
Xiufeng Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Priority to US11/978,434 priority Critical patent/US20080058423A1/en
Publication of US20080058423A1 publication Critical patent/US20080058423A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C07D203/12—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Definitions

  • the present invention relates to compounds capable of serving as moderators of human and mammalian appetite and as such provides a means for reducing body mass.
  • the compounds of the present invention are selective against melanin concentrating hormone (MCH) while not having the pernicious side effects which results from undesirable interactions at other appetite-related brain receptors.
  • MCH melanin concentrating hormone
  • the present invention relates to the surprising discovery that certain compounds (compositions of matter, analogs) bind selectively as antagonists to the MCH-R1 receptor without substantial binding to the 5-HT 2c receptor.
  • selective binding is binding to the MCH-R1 receptor at a level at least about 10 fold greater than at the 5-HT 2c receptor.
  • a compound with an IC-50 at MCH-R1 of 12 nM and an IC-50 at 5-HT 2c of 1125 nM would be a compound which is within the range of compounds considered to be a selective antagonist at the MCH-R1 receptor over the 5-HT 2c receptor.
  • the present invention encompasses three major aspects each of which have their own separate categories, aspects, iterations, and specific iterative examples.
  • the major aspects of the present invention include:
  • hydrocarbyl stands for any carbon atom-based unit (organic molecule), said units optionally containing one or more organic functional groups, including inorganic atom comprising salts, inter alia, carboxylate salts, quaternary ammonium salts.
  • organic functional groups including inorganic atom comprising salts, inter alia, carboxylate salts, quaternary ammonium salts.
  • hydrocarbyl are the terms “acyclic” and “cyclic” units which divide hydrocarbyl units into cyclic and non-cyclic classes.
  • substituted and unsubstituted C 1 -C 10 acyclic hydrocarbyl encompasses 3 categories of units:
  • substituted and unsubstituted C 1 -C 10 cyclic hydrocarbyl encompasses 5 categories of units:
  • fused ring units, as well as spirocyclic rings, bicyclic rings and the like, which comprise a single heteroatom will be considered to belong to the cyclic family corresponding to the heteroatom containing ring.
  • 1,2,3,4-tetrahydroquinoline having the formula: is, for the purposes of the present invention, considered a heterocyclic unit.
  • 6,7-Dihydro-5H-cyclopenta[b]pyridine having the formula: is, for the purposes of the present invention, considered a heteroaryl unit.
  • the aryl ring will predominate and determine the type of category to which the ring is assigned.
  • 1,2,3,4-tetrahydro-[1,8]naphthyridine having the formula: is, for the purposes of the present invention, considered a heteroaryl unit.
  • substituted is used throughout the specification.
  • substituted is defined herein as “a hydrocarbyl moiety, whether acyclic or cyclic, which has one or more hydrogen atoms replaced by a substituent or several substituents as defined herein below.
  • the units, which substituted for hydrogen atoms are capable of replacing one hydrogen atom, two hydrogen atoms, or three hydrogen atoms of a hydrocarbyl moiety at a time.
  • these substituents can replace two hydrogen atoms on two adjacent carbons to form said substituent, new moiety or unit.”
  • a substituted unit that requires a single hydrogen atom replacement includes halogen, hydroxyl, and the like.
  • a two hydrogen atom replacement includes carbonyl, oximino, and the like.
  • a two hydrogen atom replacement from adjacent carbon atoms includes epoxy, and the like.
  • a unit which encompasses a three hydrogen atom replacement includes cyano, and the like.
  • substituted is used throughout the present specification to indicate that a hydrocarbyl moiety, inter alia, aromatic ring, alkyl chain, can have one or more of the hydrogen atoms replaced by a substituent. When a moiety is described as “substituted” any number of the hydrogen atoms may be replaced.
  • 4-hydroxyphenyl is a “substituted aromatic carbocyclic ring”
  • (N,N-dimethyl-5-amino)octanyl is a “substituted C 8 alkyl unit
  • 3-guanidinopropyl is a “substituted C 3 alkyl unit”
  • 2-carboxypyridinyl is a “substituted heteroaryl unit.”
  • each R 11 is independently hydrogen, substituted or unsubstituted C 1 -C 4 linear, branched, or cyclic alkyl; or two R 11 units can be taken together to form a ring comprising 3-7 atoms.
  • R 5 units represent substitutes for hydrogen atoms on the R 3 moieties.
  • index n is greater than 0, from 1 to 5 hydrogen atoms on the rings are capable of being substituted by any substituent.
  • the compounds of the present invention are melanin concentrating hormone antagonists and comprise all enantiomeric and diasteriomeric forms and salts thereof, said antagonists having the principal naphthalene scaffold with the formula: wherein said melanin concentrating hormone antagonists have three principal parts:
  • a first principal element of the MCH antagonists of the present invention relates to R units having the formula: -(L) x -R 3 wherein R 3 is a substituted or unsubstituted aryl unit chosen from:
  • the substitutes as defined herein above are each considered suitable substitutes for hydrogen atoms on the B-ring.
  • R 5 is a unit chosen from:
  • a first iteration of Aspect 2 relates to 4′-(R 5 -substituted)-biphenyl units, for example, 4′-fluoro-biphenyl having the formula: Further non-limiting examples according to this iteration include 4′-chloro-4-biphenyl, 4′-trifluoromethyl-4-biphenyl, 4′-cyano-4-biphenyl, 4′-nitro-4-biphenyl, 4′-methyl-4-biphenyl, and 4′-methoxy-4-biphenyl.
  • a second iteration of Aspect 2 relates to 3′-(R 5 -substituted)-biphenyl units, for example, 3′-fluoro-biphenyl having the formula: Further non-limiting examples according to this iteration include 3′-chloro-4-biphenyl, 3′-trifluoromethyl-4-biphenyl, 3′-cyano-4-biphenyl, 3′-nitro-4-biphenyl, and 3′-methoxy-4-biphenyl.
  • a third iteration of Aspect 2 relates to 2′-(R 5 -substituted)-biphenyl units, for example, 2′-fluoro-biphenyl having the formula: Further non-limiting examples according to this iteration include 2′-chloro-4-biphenyl, 2′-trifluoromethyl-4-biphenyl, 2′-cyano-4-biphenyl, 2′-nitro-4-biphenyl, and 2′-methoxy-4-biphenyl.
  • a fourth iteration of Aspect 2 relates to 3′,4′-di-(R 5 -substituted)-biphenyl units, for example, 3′,4′-difluoro-biphenyl having the formula: Further non-limiting examples according to this iteration include 3′,4′-dichloro-4-biphenyl, 3′-nitro-4′-chloro-4-biphenyl, 3′-methoxy-4′-fluoro-4-biphenyl, 3′,4′-ditrifluoromethyl-4-biphenyl, 3′,4′-dicyano-4-biphenyl, 3′,4′-dinitro-4-biphenyl, and 3′,4′-dimethoxy-4-biphenyl.
  • Aspect 1 of this category of R units relates to 4-(R 5 -substituted)phenyl units, for example, 4-fluorophenyl having the formula: Further non-limiting examples according to Aspect 1 include 4-chlorophenyl, 4-methyl-phenyl, 4-methoxyphenyl, 4-trifluoromethylphenyl, 4-cyanophenyl, and 4-hydroxyphenyl.
  • Aspect 2 of this category of R units relates to di-substituted phenyl units, for example, 3,4-difluorophenyl having the formula: Further non-limiting examples of Aspect 2 include 2,4-difluorophenyl, 2,6-difluorophenyl, 3,5-difluorophenyl, 2-methoxy-3-chlorophenyl, and 2-cyano-3-methoxyphenyl.
  • a second principal element of the MCH antagonists of the present invention relates to the N-(6-substituted-naphthalen-1-yl)methylene amide units having the formula: wherein R 2 is a unit chosen from: i) hydrogen; or ii) C 1 -C 4 linear, branched, or cyclic alkyl; each R 8 is independently chosen from: i) hydrogen; ii) C 1 -C 6 substituted or unsubstituted linear, branched, or cyclic hydrocarbyl; iii) —CO 2 R 9 ; iv) two R 8 units can be taken together to form a carbonyl group; R 9 is hydrogen or C 1 -C 4 linear, branched, or cyclic alkyl; for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, cyclopropyl, cyclopropylmethyl
  • N-(6-substituted-naphthalen-1-yl)methylene amide units are the core and together with the 4′-substituted-4-biphenyl units and amino units comprising a basic, nitrogen atom, make up the compounds of the present invention.
  • the first category of the core units relates to core units having the formula: wherein R 2 is hydrogen and each R 8 unit is hydrogen.
  • Compounds comprising Category I of the invention as described herein below contain a N-(6-substituted-naphthalen-1-yl)methylene unit as their core unit.
  • the second category of the core units relates to core units having the formula: wherein R 2 is methyl and each R 8 unit is hydrogen.
  • Compounds comprising Category II of the invention as described herein below contain a N-(6-substituted-naphthalen-1-yl)methylene unit as their core unit.
  • a third principal element of the MCH antagonists of the present invention relates to the R 1 amino units comprising a basic nitrogen atom having the formula: -(L 1 ) y -R 4 R 4 has the formula: R 6 and R 7 are each independently chosen from:
  • R 1 units relate to units wherein R 6 and R 7 are each independently hydrogen or C 1 -C 8 linear hydrocarbyl.
  • the first iteration of Aspect 1 relates to R 6 and R 7 are each independently chosen from hydrogen, methyl, and ethyl. This iteration includes amino units chosen from —NH 2 , —NH(CH 3 ), —NH(CH 2 CH 3 ), —N(CH 3 ) 2 , —N(CH 3 )(CH 2 CH 3 ), and —N(CH 2 CH 3 ) 2 .
  • R 6 and R 7 are each independently chosen from hydrogen, propyl, isopropyl, n-butyl, and n-pentyl.
  • This iteration includes amino units chosen from —NH(CH 2 CH 2 CH 3 ), —N(CH 2 CH 2 CH 3 ) 2 , —NH[CH 2 (CH 3 ) 2 ], —N[CH 2 (CH 3 ) 2 ] 2 , —NH(CH 2 CH 2 CH 2 CH 3 ), —N(CH 2 CH 2 CH 2 CH 3 ) 2 , and —N[(CH 2 ) 4 CH 3 ] 2 .
  • R 1 units relate to units wherein R 6 and R 7 are taken together to form a heterocyclic ring having from 3 to 8 atoms.
  • rings which can be formed from R 6 and R 7 include: aziridin-1-yl, azetidin-1-yl, pyrrolidin-1-yl, 3-pyrrolin-1-yl, imidazolidin-1-yl, pyrazolidin-1-yl, piperidine-1-yl, piperazin-1-yl, 4-substituted-piperazin-1-yl, azepan-1-yl, and morpholin-4-yl.
  • L and L 1 are linking units each of which is selected independently of the other.
  • L is absent; when x is equal to 1, L is present.
  • L 1 is absent; when y is equal to 1, L 1 is present.
  • each R 10 is independently chosen from: i) hydrogen; ii) C 1 -C 6 substituted or unsubstituted linear, branched, or cyclic hydrocarbyl; iii) —CO 2 R 9 ; iv) —CN; two R 10 units on the same carbon are be taken together to form a carbonyl group; or R 10 units from two adjacent linking units are taken together to form a double bond; R 9 is hydrogen or C 1 -C 4 linear, branched, or cyclic alkyl.
  • the index z indicates the number of L or L 1 units which are present.
  • the index z has the value form 1 to 3. For example, when an L or L 1 unit is present and the index z for that unit is equal to 1, the L or L 1 unit will have the formula: Likewise when the index z is equal to 2, the L or L 1 unit which is present will have the formula:
  • Aspect 2 of linking units relates to compounds wherein L is a unit having the formula: and R 10 is a unit selected from hydrogen, —CN, —CH 3 , or —NO 2 .
  • a non-limiting example of an analog according to the present invention comprising the second aspect of linking units is 2-cyano-N-methyl-3-phenyl-N-(6-pyrrolidin-1-ylmethyl-naphthalen-1-ylmethyl)-acrylamide.
  • the compounds of Aspect 2 also contain an L 1 unit which is a methylene unit.
  • the compounds of the present invention are 6-(amino unit comprising)-1-amidomethyl-naphthalenes having the general formula: wherein R comprises an aryl unit, R 1 comprises a basic amino nitrogen, and R 2 is hydrogen or a hydrocarbyl unit described herein below.
  • the compounds of the present invention are given chemical names which are viewed as derivatives of the R unit carboxylic acid, for example, the compound having the formula: is named herein as N-(6-dimethylaminomethyl-naphthylen-1-ylmethyl)-4-fluorobenzamide and the compound having the formula: is named 4′-Fluoro-biphenyl-4-carboxylic acid (6-dimethylaminomethyl-naphthalen-1-ylmethyl)-amide.
  • any exceptions to this naming scheme will be clear to the artisan of ordinary skill and not diminish from the description of the present invention.
  • analogs (compounds) of the present invention are arranged in several categories to assist the formulator in applying a rational synthetic strategy for the preparation of analogs which are not expressly exampled herein.
  • the arrangement into categories does not imply increased or decreased efficacy or utility for any of the compositions of matter, compositions, or methods described herein.
  • Category I of the present invention relates to compounds with a core scaffold having the formula: wherein L is absent and the R 3 unit is a substituted biphenyl thereby providing a core scaffold with the general formula:
  • the first aspect of Category I relates to R 4 units having the formula:
  • R 6 and R 7 units each independently comprise hydrogen or C 1 -C 8 substituted or unsubstituted linear or branched hydrocarbyl as further described herein below in Table I. TABLE I No. R 3 R 4 1 4-biphenyl —NH 2 2 4-biphenyl —NHCH 3 3 4-biphenyl —N(CH 3 ) 2 4 4-biphenyl —NH(C 2 H 5 ) 5 4-biphenyl —N(C 2 H 5 ) 2 6 3′-fluoro-4-biphenyl —NH 2 7 3′-fluoro-4-biphenyl —NHCH 3 8 3′-fluoro-4-biphenyl —N(CH 3 ) 2 9 3′-fluoro-4-biphenyl —NH(C 2 H 5 ) 10 3′-fluoro-4-biphenyl —N(C 2 H 5 ) 2 11 3′-chloro-4-biphenyl —
  • the second aspect of Category I relates to compounds having a substituted biphenyl R 3 unit providing a core scaffold with the general formula: wherein R 4 unit have the formula:
  • R 6 and R 7 units are taken together to from a heterocyclic or heteroaryl ring having from 3 to 8 atoms as further described herein below in Table II.
  • Table II No.
  • R 3 R 4 66
  • 4-biphenyl aziridin-1-yl 67
  • 4-biphenyl pyrrolidin-1-yl 68
  • 4-biphenyl piperidin-1-yl 69
  • 4-biphenyl morpholin-4-yl 71 4-biphenyl azepan-1-yl 72 3′-fluoro-4-biphenyl aziridin-1-yl 73 3′-fluoro-4-biphenyl pyrrolidin-1-yl 74
  • 3′-fluoro-4-biphenyl piperidin-1-yl 75
  • 3′-fluoro-4-biphenyl piperazin-1-yl 76 3′-fluoro-4
  • the compounds which comprise the first and second aspect of Category I, wherein R 2 is equal to hydrogen can be prepared by the procedure described herein below and outlined in Scheme I.
  • the artisan can substitute other procedures which facilitate the achievement of higher yields, purity, or which utilize readily available starting materials that can be introduced into the procedures outlined herein below.
  • step (c) for the formation of intermediate 3, the artisan can substitute a different reagent when preparing the acid chloride, inter alia, thionyl chloride.
  • step (d) of Scheme I below wherein intermediate 4 is prepared
  • the other aspects or iterations of this aspect of Category I can be prepared by the artisan substituting H 3 , NH 2 CH 3 , NH(CH 2 CH 3 ) 2 , NH(CH 3 )(CH 2 CH 3 ), NH 2 (CH 2 CH 3 ), NH 2 [CH(CH 3 ) 2 ], and NH[CH(CH 3 ) 2 ] 2 , as well as other NHR 6 R 7 amines wherein R 6 and R 7 are each independently C 1 -C 8 substituted or unsubstituted linear or branched hydrocarbyl units, for NH(CH 3 ) 2 in step (d).
  • the conditions may be necessarily adjusted by the formulator using practices standard and known to the skilled artisan.
  • R 6 and R 7 can be taken together to form a heterocyclic ring having from 3 to 8 atoms, aziridine, pyrrolidine, piperidine, piperazine, 1H-azepine, and morpholine, for example, these rings can be substituted for NH(CH 3 ) 2 in step (d) of Scheme I herein below.
  • the conditions may be necessarily adjusted by the formulator using practices standard and known to the skilled artisan.
  • Category II of the present invention relates to compounds with a core scaffold having the formula: and a substituted biphenyl R 3 unit providing a core scaffold with the general formula:
  • the first aspect of Category II relates to R 4 units having the formula:
  • R 6 and R 7 units each independently comprise hydrogen or C 1 -C 8 substituted or unsubstituted linear or branched hydrocarbyl as further described herein below in Table III TABLE III No.
  • R 3 R 4 144 4-biphenyl —NH 2 145 4-biphenyl —NHCH 3 146
  • 4-biphenyl —N(C 2 H 5 ) 2 149 3′-fluoro-4-biphenyl —NH 2 150 3′-fluoro-4-biphenyl —NHCH 3 151 3′-fluoro-4-biphenyl —N(CH 3 ) 2 152 3′-fluoro-4-biphenyl —NH(C 2 H 5 ) 153 3′-fluoro-4-biphenyl —N(C 2 H 5 ) 2 154 3
  • the second aspect of Category II relates to compounds having a substituted biphenyl R 3 with the general formula: wherein R 4 units have the formula:
  • R 6 and R 7 units are taken together to from a heterocyclic or heteroaryl ring having from 3 to 8 atoms as further described herein below in Table IV TABLE IV No.
  • R 3 R 4 209 4-biphenyl aziridin-1-yl 210 4-biphenyl pyrrolidin-1-yl 211 4-biphenyl piperidin-1-yl 212 4-biphenyl piperazin-1-yl 213 4-biphenyl morpholin-4-yl 214 4-biphenyl azepan-1-yl 215 3′-fluoro-4-biphenyl aziridin-1-yl 216 3′-fluoro-4-biphenyl pyrrolidin-1-yl 217 3′-fluoro-4-biphenyl piperidin-1-yl 218 3′-fluoro-4-biphenyl piperazin-1-yl 219 3′-fluoro-4-biphenyl morpholin-4-y
  • R 6 and R 7 can be taken together to form a heterocyclic ring having from 3 to 8 atoms, aziridine, pyrrolidine, piperidine, piperazine, 1H-azepine, and morpholine, for example, can be substituted for NH(CH 3 ) 2 in step (d) of Scheme I herein above.
  • the conditions may be necessarily adjusted by the formulator using practices standard and known to the skilled artisan.
  • Each of the disease states or conditions which the formulator desires to treat may require differing levels or amounts of the compounds described herein to obtain a therapeutic level.
  • the formulator can determine this amount by any of the common testing procedures known to the artisan.
  • the present invention also relates to compositions or formulations which comprise the melanin concentrating hormone (MCH) antagonists according to the present invention.
  • MCH melanin concentrating hormone
  • the compositions of the present invention comprise:
  • excipient and “carrier” are used interchangeably throughout the description of the present invention and said terms are defined herein as, “ingredients which are used in the practice of formulating a safe and effective pharmaceutical composition.”
  • excipients are used primarily to serve in delivering a safe, stable, and functional pharmaceutical, serving not only as part of the overall vehicle for delivery but also as a means for achieving effective absorption by the recipient of the active ingredient.
  • An excipient may fill a role as simple and direct as being an inert filler, or an excipient as used herein may be part of a pH stabilizing system or coating to insure delivery of the ingredients safely to the stomach.
  • the formulator can also take advantage of the knowledge that selected compounds of the present invention have improved cellular potency, pharmacokinetic properties, as well as improved oral bioavailability.
  • compositions according to the present invention include:
  • an effective amount means “an amount of one or more melanin concentrating hormone antagonists, effective at dosages and for periods of time necessary to achieve the desired result.”
  • An effective amount may vary according to factors known in the art, such as the disease state, age, sex, and weight of the human or animal and affinity of drug for target receptor being treated.
  • dosage regimes may be described in examples herein, a person skilled in the art would appreciated that the dosage regime may be altered to provide optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
  • the compositions of the present invention can be administered as frequently as necessary to achieve a therapeutic amount.
  • compositions which are anti-obesity compositions and therefore provide body weight control or maintenance of weight loss comprise:
  • body weight control or maintenance of weight loss is defined herein as “the ability of a compound of the present invention to provide effective loss of body mass and to provide an effective maintenance of body mass at a particular body mass value (body weight).”
  • compositions which are body weight gain controlling compositions and therefore provide weight gain control the compositions of the present invention comprise:
  • compositions which are anxiolytic and antidepressant compositions and therefore provide control of anxiety and/or relief from depression comprise:
  • compositions of this invention are typically provided in unit dosage form.
  • unit dosage form is defined herein as comprising an effective amount of one or more melanin concentrating hormone antagonists.
  • the compositions of the present invention contain in one embodiment from about 0.1 mg to about 5000 mg of one or more melanin concentrating hormone antagonists, while in other embodiments the compositions comprise from about 10 mg to about 500 mg, or from about 100 mg to about 1000 mg respectively.
  • Non-limiting examples of substances which can serve as pharmaceutically-acceptable excipients or components thereof are sugars, inter alia, lactose, glucose and sucrose, sorbitol, mannitol; starches, inter alia, corn starch and potato starch; cellulose and its derivatives, inter alia, sodium carboxymethyl cellulose, ethyl cellulose, and methyl cellulose; powdered tragacanth; malt; gelatin; talc; solid lubricants, such as stearic acid and magnesium stearate; vegetable oils, propylene glycol, glycerin, and polyethylene glycol; agar; alginic acid; wetting agents and lubricants, inter alia, sodium lauryl sulfate; coloring agents; flavoring agents; tableting agents, stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic saline; and buffers.
  • sugars inter alia, lactose, glucose and sucrose,
  • the compounds of the present invention are useful in treating disorders that are mediated by MCH through the MCH receptor.
  • Additional disorders other than obesity and food intake related illnesses that are mediated by MCH through the MCH receptor are thyroid hormone secretion, diuresis and water/electrolyte homeostasis, memory, sleep and arousal, anxiety and depression, seizure and in treatment of neurodegeneration or psychiatric disorders.
  • the compounds of the present invention have improved cellular potency and pharmacokinetic properties and this advantage is made use of by the fact the third aspect of the present invention as a whole, relates to a method for controlling obesity, and the subsequent weight management after weight loss. This is achieved by administering to a human or a higher mammal an effective amount of one or more of the compounds (analogs) as described herein.
  • MCH Melanin Concentrating Hormone
  • MCH melanin concentrating hormone
  • melanin concentrating hormone antagonists of the present invention are discrete chemical entities, the method of delivery or the method of use may be coupled with other suitable drug delivery systems.
  • a drug delivery technique useful for the compounds of the present invention is the conjugation of the compound to an active molecule capable of being transported through a biological barrier. 4
  • a specific example constitutes the coupling of the compound of the invention to fragments of insulin to achieve transport across the blood brain barrier. 5
  • the compounds of the present invention which are selective antagonists at the MCH-R1 receptor over the 5-HT 2c receptor are suitable for use the following:
  • a method for controlling the body weight of humans and higher mammals comprising administering to a human or higher mammal an effective amount of one or more selective antagonist of the present invention, including all enantiomeric and diasteriomeric forms and salts thereof.
  • a method for controlling weight gain in humans and higher mammals comprising administering to a human or higher mammal an effective amount of one or more selective antagonist of the present invention, including all enantiomeric and diasteriomeric forms and salts thereof.
  • a method for controlling anxiety in humans and higher mammals comprising administering to a human or higher mammal an effective amount of one or more selective antagonist of the present invention, including all enantiomeric and diasteriomeric forms and salts thereof.
  • a method for controlling depression in humans and higher mammals comprising administering to a human or higher mammal an effective amount of one or more selective antagonist of the present invention, including all enantiomeric and diasteriomeric forms and salts thereof.
  • a method for controlling in humans one or more diseases, disease states, conditions, or syndromes resulting from body weight disorders said diseases, disease states, conditions, or syndromes are chosen from insulin resistance, glucose intolerance, Type-2 diabetes mellitus, coronary artery disease, elevated blood pressure, hypertension, dyslipidaemia, menstrual irregularities, hirsutism, gallbladder disease, restrictive lung disease, sleep apnea, gout, osteoarthritis, and thromboembolic disease, said method comprising administering to a human an effective amount of one or more selective antagonist of the present invention, including all enantiomeric and diasteriomeric forms and salts thereof.
  • In vitro binding and function assays are performed on membranes derived from cells or tissues expressing endogenous MCH1R. Competition binding assays are performed to identify high affinity compounds. Briefly, either radiolabeled or europium labeled MCH with varying concentrations of competitor compound which are incubated with membranes expressing the receptor. Rat brain membrane or cell lines, including but not limited to human Kelly neuroblastoma cells, A-431 epidermoid cells, and rat PC-12 cells are known to express endogenous MCH1R and are used in the assay. Binding is allowed to proceed until equilibrium is reached then bound labeled MCH is separated from free MCH by capturing membranes onto a filter. The filters are washed to remove loosely associated MCH and labeled MCH is quantified. Data is analyzed and IC 50 and K i are calculated to determine compound affinity.
  • MCH function assays are performed in an analogous manner to the binding assay. Competition assays are performed with a single concentration of MCH and varying concentrations of compound. Function is assayed using GTP binding or a functional response (e.g. Calcium uptake, MAP/ERK activation) because the MCH1R is a G-protein coupled receptor that couples the G i/o , and G q proteins and has been shown to elicit these cellular functional responses.
  • the assay can be performed on the same membranes as used for the binding assays. There are readily available kits for measuring GTP binding to membranes (e.g. Perkin Elmer Life Sciences). Data is analyzed and IC 50 values are generated to determine whether the compound is an agonist or antagonist.
  • MCH antagonist compounds are evaluated for binding to the serotonin 5-HT 2c receptor to determine receptor selectivity. Binding activity is assessed using a competitive assay with 3 H-mesulergine (Perkin Elmer), a 5-HT 2c selective ligand, on membrane containing the 5-HT 2c receptor. Briefly, 1 nM 3 H-mesulergine and varying concentrations of the compound are incubated with 5-HT 2c receptor membranes, following an incubation period, the membranes are washed and 3H-mesulergine bound to membranes is measured in a liquid scintillation counter.
  • 3 H-mesulergine Perkin Elmer
  • the amount of bound 3 H-mesulergine at the varying concentration of competitor compound is used to derive the affinity (K i ) of the compound for the 5-HT 2c receptor.
  • 5-HT 2c receptor containing membranes are readily available from several companies including Perkin-Elmer and Euroscreen.
  • MCH-1R selectivity of a compound relative to 5-HT 2c is defined herein as the ratio of the EC 50 of the compound for an MCH-1R receptor (“MCH-1R-EC 50 ”) over the EC 50 of the compound for the 5-HT 2c (5-HT 2c -EC 50 ) receptor, the EC 50 values being measured as described above.
  • MCH -1 R/ 5- HT 2c selectivity [ MCH -1 R - EC 50 ]/[5- HT 2c - EC 50 ]
  • a “selective binding” is binding to the MCH-R1 receptor at a level at least about 10 fold greater than at the 5-HT 2c receptor.
  • a compound with an IC-50 at MCH-R1 of 12 nM and an IC-50 at 5-HT 2c of 1125 nM would be a compound which is a selective antagonist at the MCH-R1 receptor over the 5-HT 2c receptor.
  • this value is at least about 100, while for yet other embodiments of the present invention the selectivity is at least about 1000.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to compounds capable of serving as moderators of human and mammalian appetite and as such provide a means for reducing body mass and controlling obesity.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is a divisional of U.S. application Ser. No. 11/180,814, filed Jul. 13, 2005 which claims priority under Title 35, U.S. Provisional Application Ser. No. 60/588,209, filed Jul. 15, 2004.
    • FIELD OF THE INVENTION
  • The present invention relates to compounds capable of serving as moderators of human and mammalian appetite and as such provides a means for reducing body mass. The compounds of the present invention are selective against melanin concentrating hormone (MCH) while not having the pernicious side effects which results from undesirable interactions at other appetite-related brain receptors.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention relates to the surprising discovery that certain compounds (compositions of matter, analogs) bind selectively as antagonists to the MCH-R1 receptor without substantial binding to the 5-HT2c receptor. What is meant herein by “selective binding” is binding to the MCH-R1 receptor at a level at least about 10 fold greater than at the 5-HT2c receptor. For example, a compound with an IC-50 at MCH-R1 of 12 nM and an IC-50 at 5-HT2c of 1125 nM would be a compound which is within the range of compounds considered to be a selective antagonist at the MCH-R1 receptor over the 5-HT2c receptor.
  • The present invention encompasses three major aspects each of which have their own separate categories, aspects, iterations, and specific iterative examples. The major aspects of the present invention include:
      • i) compositions of matter which are selective antagonists for MCH-R1 receptors over 5-HT2c receptors;
      • ii) compositions and pharmaceutical compositions (matrices) comprising said compositions of matter, and
      • iii) methods for controlling, abating, preventing, or otherwise alleviating diseases or the symptoms of disease states related to body mass, said diseases or the symptoms of disease states being controlled by administration of said compositions of matter to a human or mammal, whether said composition of matter is administered alone or in a composition or within a pharmaceutical composition (matrix).
  • The following chemical hierarchy is used throughout the specification to particularly point out and distinctly claim the units which comprise the compounds of the present invention. The term “hydrocarbyl” stands for any carbon atom-based unit (organic molecule), said units optionally containing one or more organic functional groups, including inorganic atom comprising salts, inter alia, carboxylate salts, quaternary ammonium salts. Encompassed within the term “hydrocarbyl” are the terms “acyclic” and “cyclic” units which divide hydrocarbyl units into cyclic and non-cyclic classes.
  • 1. Substituted and unsubstituted C1-C10 acyclic hydrocarbyl:
  • For the purposes of the present invention the term “substituted and unsubstituted C1-C10 acyclic hydrocarbyl” encompasses 3 categories of units:
    • i) C1-C10 linear or branched alkyl, non-limiting examples of which include, methyl (C1), ethyl (C2), n-propyl (C3), iso-propyl (C3), n-butyl (C4), sec-butyl (C4), isobutyl (C4), tert-butyl (C4), and the like; substituted C1-C10 linear or branched alkyl, non-limiting examples of which includes, hydroxymethyl (C1), chloromethyl (C1), trifluoromethyl (C1), aminomethyl (C1), 1-chloroethyl (C2), 2-hydroxyethyl (C2), 1,2-difluoroethyl (C2), 3-carboxypropyl (C3), and the like.
    • ii) C2-C10 linear or branched alkenyl, non-limiting examples of which include, ethenyl (C2), 3-propenyl (C3), 1-propenyl (also 2-methylethenyl) (C3), isopropenyl (also 2-methylethen-2-yl) (C3), buten-4-yl (C4), and the like; substituted C2-C10 linear or branched alkenyl, non-limiting examples of which includes, 2-chloroethenyl (also 2-chlorovinyl) (C2), 4-hydroxybuten-1-yl (C4), 7-hydroxy-7-methyloct-4-en-2-yl (C9), 7-hydroxy-7-methyloct-3,5-dien-2-yl (C9), and the like.
    • iii) C2-C10 linear or branched alkynyl, non-limiting examples of which include, ethynyl (C2), prop-2-ynyl (also propargyl) (C3), propyn-1-yl (C3), and 2-methylhex-4-yn-1-yl (C7); substituted C2-C10 linear or branched alkynyl, non-limiting examples of which includes, 5-hydroxy-5-methylhex-3-ynyl (C7), 6-hydroxy-6-methylhept-3-yn-2-yl (C8), 5-hydroxy-5-ethylhept-3-ynyl (C9), and the like.
      2. Substituted and unsubstituted C1-C10 cyclic hydrocarbyl:
  • For the purposes of the present invention the term “substituted and unsubstituted C1-C10 cyclic hydrocarbyl” encompasses 5 categories of units:
    • i) C3-C10 carbocyclic units, non-limiting examples of which include, cyclopropyl (C3), cyclobutyl (C4), cyclopentyl (C5), cyclohexyl (C6), cycloheptyl (C7), decalinyl (C10), decahydro-azulenyl (C10), and the like; substituted C3-C10 carbocyclic units, non-limiting examples of which includes, 2-methylcyclopropyl (C3), 2,5-dimethylcyclopentyl (C5), 4-tert-butylcyclopentyl (C5), 3,5-dichlorocyclohexyl (C6), 4-hydroxy-cyclohexyl (C6), and the like.
    • ii) C6-C10 aryl units which include, phenyl, naphthen-1-yl, and naphthen-2-yl; substituted C6-C10 aryl units, non-limiting examples of which includes, 4-fluorophenyl (C6), 2,6-di-tert-butylphenyl (C6), 3-hydroxyphenyl (C6), 8-hydroxynaphthylen-2-yl (C10), 6-cyano-naphthylen-1-yl (C10), and the like.
    • iii) C1-C10 heterocyclic units, non-limiting examples of which include, 1,2,3,4-tetrazolyl (C1), aziridinyl (C2), oxazolyl (C3), tetrahydrofuranyl (C4), dihydropyranyl (C5), piperidin-2-one (valerolactam) (C5), 2,3,4,5-tetrahydro-1H-azepinyl (C6), 2,3-dihydro-1H-indole (C8), 1,2,3,4-tetrahydro-quinoline (C9), and the like; substituted C1-C10 heterocyclic units, non-limiting examples of which include, 2-amino-4,5-dihydro-3H-pyrrolyl (C4), N-methylmorpholinyl (C4), 2,6-dimethylpiperazinyl (C4), and the like.
    • iv) C1-C10 heteroaryl units, non-limiting examples of which include: triazinyl (C3), furanyl (C4), thiophenyl (C4), pyrimidinyl (C4), pyridinyl (C5), 6,7-dihydro-5H-cyclopenta[b]pyridine (C8), and the like; substituted C1-C10 heteroaryl units, non-limiting examples of which include, 4-dimethylaminopyridinyl (C5), 2-methylindolyl (C8), and the like.
    • v) C1-C12 tethered cyclic hydrocarbyl units (whether C3-C10 carbocyclic units, C6-C10 aryl units, C1-C10 heterocyclic units, or C1-C10 heteroaryl units) which connected to another moiety, unit, or core of the molecule by way of a C1-C6 alkylene unit. Non-limiting examples of tethered cyclic hydrocarbyl units include benzyl C1-(C6) having the formula:
      Figure US20080058423A1-20080306-C00001
      • wherein Ra is optionally one or more independently chosen substitutions for hydrogen. Further examples include other aryl units, inter alia, naphthalen-2-ylmethyl C1-(C10), 4-fluorobenzyl C1-(C6), 2-(3-hydroxy-phenyl)ethyl C2-(C6), as well as substituted and unsubstituted C3-C10 alkylenecarbocyclic units, for example, cyclopropylmethyl C1-(C3), cyclopentylethyl C2-(C5), cyclohexylmethyl C1-(C6). Included within this category are substituted and unsubstituted C1-C10 alkylene-heteroaryl, for example a 2-picolyl C1-(C6) unit having the formula:
        Figure US20080058423A1-20080306-C00002
      • wherein Ra is the same as defined above. In addition, C1-C12 tethered cyclic hydrocarbyl units include C1-C10 alkyleneheterocyclic units, non-limiting examples of which include, aziridinylmethyl C1-(C2) and oxazol-2-ylmethyl C1-(C3).
  • For the purposed of the present invention fused ring units, as well as spirocyclic rings, bicyclic rings and the like, which comprise a single heteroatom will be considered to belong to the cyclic family corresponding to the heteroatom containing ring. For example, 1,2,3,4-tetrahydroquinoline having the formula:
    Figure US20080058423A1-20080306-C00003
    is, for the purposes of the present invention, considered a heterocyclic unit. 6,7-Dihydro-5H-cyclopenta[b]pyridine having the formula:
    Figure US20080058423A1-20080306-C00004
    is, for the purposes of the present invention, considered a heteroaryl unit. When a fused ring unit contains heteroatoms in both a saturated and an aryl ring, the aryl ring will predominate and determine the type of category to which the ring is assigned. For example, 1,2,3,4-tetrahydro-[1,8]naphthyridine having the formula:
    Figure US20080058423A1-20080306-C00005
    is, for the purposes of the present invention, considered a heteroaryl unit.
  • The term “substituted” is used throughout the specification. The term “substituted” is defined herein as “a hydrocarbyl moiety, whether acyclic or cyclic, which has one or more hydrogen atoms replaced by a substituent or several substituents as defined herein below. The units, which substituted for hydrogen atoms are capable of replacing one hydrogen atom, two hydrogen atoms, or three hydrogen atoms of a hydrocarbyl moiety at a time. In addition, these substituents can replace two hydrogen atoms on two adjacent carbons to form said substituent, new moiety or unit.” For example, a substituted unit that requires a single hydrogen atom replacement includes halogen, hydroxyl, and the like. A two hydrogen atom replacement includes carbonyl, oximino, and the like. A two hydrogen atom replacement from adjacent carbon atoms includes epoxy, and the like. A unit which encompasses a three hydrogen atom replacement includes cyano, and the like. The term substituted is used throughout the present specification to indicate that a hydrocarbyl moiety, inter alia, aromatic ring, alkyl chain, can have one or more of the hydrogen atoms replaced by a substituent. When a moiety is described as “substituted” any number of the hydrogen atoms may be replaced. For example, 4-hydroxyphenyl is a “substituted aromatic carbocyclic ring”, (N,N-dimethyl-5-amino)octanyl is a “substituted C8 alkyl unit, 3-guanidinopropyl is a “substituted C3 alkyl unit,” and 2-carboxypyridinyl is a “substituted heteroaryl unit.”
  • The following are non-limiting examples of units which can substitute for hydrogen atoms on a hydrocarbyl or other unit:
  • i) —OR11;
  • ii) —C(O)R11;
  • iii) —C(O)OR11
  • iv) —C(O)N(R11)2;
  • v) —CN;
  • vi) —N(R11)2;
  • vii) -halogen;
  • viii) —CF3, —CCl3, —CBr3; and
  • ix) —SO2R11
  • wherein each R11 is independently hydrogen, substituted or unsubstituted C1-C4 linear, branched, or cyclic alkyl; or two R11 units can be taken together to form a ring comprising 3-7 atoms.
  • As described further herein below, R5 units represent substitutes for hydrogen atoms on the R3 moieties. When the index n is greater than 0, from 1 to 5 hydrogen atoms on the rings are capable of being substituted by any substituent.
  • Melanin Concentrating Hormone Antagonists
  • The compounds of the present invention are melanin concentrating hormone antagonists and comprise all enantiomeric and diasteriomeric forms and salts thereof, said antagonists having the principal naphthalene scaffold with the formula:
    Figure US20080058423A1-20080306-C00006
    wherein said melanin concentrating hormone antagonists have three principal parts:
      • a) R units having the formula:
        -(L)x-R3
        • wherein R3 comprises an aryl unit chosen from:
        • i) substituted or unsubstituted phenyl units having the formula:
          Figure US20080058423A1-20080306-C00007
        • ii) substituted or unsubstituted biphenyl units having the formula:
          Figure US20080058423A1-20080306-C00008
        • the index x is 0 or 1, each index n is independently from 0 to 5;
      • b) a core N-(6-substituted-naphthalen-1-yl)methylene amide unit having the formula:
        Figure US20080058423A1-20080306-C00009
      • c) an amino unit comprising a basic nitrogen atom having the formula:
        Figure US20080058423A1-20080306-C00010
        • the index y is 0 or 1.
          Substituted or Unsubstituted Aryl Units
  • A first principal element of the MCH antagonists of the present invention relates to R units having the formula:
    -(L)x-R3
    wherein R3 is a substituted or unsubstituted aryl unit chosen from:
  • i) phenyl units having the formula:
    Figure US20080058423A1-20080306-C00011
  • ii) biphenyl units having the formula:
    Figure US20080058423A1-20080306-C00012
    and L is an optionally present linking group defined herein below. When the index x is equal to 1 the linking unit L is present and serves to link R3 to the core N-(6-substituted-naphthalen-1-yl)methylene amide unit.
    First Category of R Units
  • The first category of R units relates to substituted and unsubstituted biphenyl units which are absent the L linking unit (index x=0), said unit having the formula:
    Figure US20080058423A1-20080306-C00013
    wherein the B-ring of the biphenyl unit either comprises all hydrogen atoms (index n=0) or the B-ring is substituted with from 1 to 5 units for hydrogen. The substitutes as defined herein above are each considered suitable substitutes for hydrogen atoms on the B-ring.
  • Aspect 1 of this category of R units relates to units having no substitutions for hydrogen (index n=0) wherein R is a 4-biphenyl unit.
  • Aspect 2 of this category of R units relates to units having one or more substitutes R5 present wherein R5 is a unit chosen from:
      • i) halogen; for example, fluoro, chloro, or bromo;
      • ii) C1-C3 linear or branched alkyl; for example, methyl (C1), ethyl (C2), n-propyl (C3), or isopropyl (C3);
      • iii) C1-C3 linear or branched alkoxy; for example, methoxy (C1), ethoxy (C2), n-propoxy (C3), or isopropoxy (C3);
      • iv) C1-C2 haloalkyl; for example, trifluoromethyl (C1), 2,2,2-trifluorethyl (C2), and trichloromethyl (C1);
      • v) cyano;
      • yl)hydroxyl; and
      • vii) —CO2R9
        wherein R9 is hydrogen or C1-C4 linear, branched, or cyclic alkyl, said units chosen from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and tert-butyl.
  • A first iteration of Aspect 2 relates to 4′-(R5-substituted)-biphenyl units, for example, 4′-fluoro-biphenyl having the formula:
    Figure US20080058423A1-20080306-C00014
    Further non-limiting examples according to this iteration include 4′-chloro-4-biphenyl, 4′-trifluoromethyl-4-biphenyl, 4′-cyano-4-biphenyl, 4′-nitro-4-biphenyl, 4′-methyl-4-biphenyl, and 4′-methoxy-4-biphenyl.
  • A second iteration of Aspect 2 relates to 3′-(R5-substituted)-biphenyl units, for example, 3′-fluoro-biphenyl having the formula:
    Figure US20080058423A1-20080306-C00015
    Further non-limiting examples according to this iteration include 3′-chloro-4-biphenyl, 3′-trifluoromethyl-4-biphenyl, 3′-cyano-4-biphenyl, 3′-nitro-4-biphenyl, and 3′-methoxy-4-biphenyl.
  • A third iteration of Aspect 2 relates to 2′-(R5-substituted)-biphenyl units, for example, 2′-fluoro-biphenyl having the formula:
    Figure US20080058423A1-20080306-C00016
    Further non-limiting examples according to this iteration include 2′-chloro-4-biphenyl, 2′-trifluoromethyl-4-biphenyl, 2′-cyano-4-biphenyl, 2′-nitro-4-biphenyl, and 2′-methoxy-4-biphenyl.
  • A fourth iteration of Aspect 2 relates to 3′,4′-di-(R5-substituted)-biphenyl units, for example, 3′,4′-difluoro-biphenyl having the formula:
    Figure US20080058423A1-20080306-C00017
    Further non-limiting examples according to this iteration include 3′,4′-dichloro-4-biphenyl, 3′-nitro-4′-chloro-4-biphenyl, 3′-methoxy-4′-fluoro-4-biphenyl, 3′,4′-ditrifluoromethyl-4-biphenyl, 3′,4′-dicyano-4-biphenyl, 3′,4′-dinitro-4-biphenyl, and 3′,4′-dimethoxy-4-biphenyl.
  • Other Aspects which relate to the first category of R units are, however, not limited to those described herein above. For example, 3′,5′-difluoro-biphenyl-4-carboxylic acid (6-dimethylaminomethyl-naphthalen-1-ylmethyl)-amide, a compound encompassed within the present invention, would be included in a further aspect, and can be formed by the procedure of Scheme I wherein 3′,5′-difluoro-biphenyl-4-carboxylic acid is substituted for 4′-fluoro-biphenyl-4-carboxylic acid.
  • Second Category of R Units
  • The second category of R units relates to units having the formula:
    Figure US20080058423A1-20080306-C00018
    wherein a linking unit as defined herein below is present (index x=1) and one or more R5 units are present, said R5 units chosen from:
      • i) halogen; for example, fluoro, chloro, or bromo;
      • ii) C1-C3 linear or branched alkyl; for example, methyl (C1), ethyl (C2), n-propyl (C3), or isopropyl (C3);
      • iii) C1-C3 linear or branched alkoxy; for example, methoxy (C1), ethoxy (C2), n-propoxy (C3), or isopropoxy (C3);
      • iv) C1-C2 haloalkyl; for example, trifluoromethyl (C1), 2,2,2-trifluorethyl (C2), and trichloromethyl (C1);
      • v) cyano; and
      • vi) hydroxyl.
  • Aspect 1 of this category of R units relates to 4-(R5-substituted)phenyl units, for example, 4-fluorophenyl having the formula:
    Figure US20080058423A1-20080306-C00019
    Further non-limiting examples according to Aspect 1 include 4-chlorophenyl, 4-methyl-phenyl, 4-methoxyphenyl, 4-trifluoromethylphenyl, 4-cyanophenyl, and 4-hydroxyphenyl.
  • Aspect 2 of this category of R units relates to di-substituted phenyl units, for example, 3,4-difluorophenyl having the formula:
    Figure US20080058423A1-20080306-C00020
    Further non-limiting examples of Aspect 2 include 2,4-difluorophenyl, 2,6-difluorophenyl, 3,5-difluorophenyl, 2-methoxy-3-chlorophenyl, and 2-cyano-3-methoxyphenyl.
    Core N-(6-substituted-naphthalen-1-yl)methylene Amide Units
  • A second principal element of the MCH antagonists of the present invention relates to the N-(6-substituted-naphthalen-1-yl)methylene amide units having the formula:
    Figure US20080058423A1-20080306-C00021
    wherein R2 is a unit chosen from:
    i) hydrogen; or
    ii) C1-C4 linear, branched, or cyclic alkyl;
    each R8 is independently chosen from:
    i) hydrogen;
    ii) C1-C6 substituted or unsubstituted linear, branched, or cyclic hydrocarbyl;
    iii) —CO2R9;
    iv) two R8 units can be taken together to form a carbonyl group;
    R9 is hydrogen or C1-C4 linear, branched, or cyclic alkyl; for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, cyclopropyl, cyclopropylmethyl, and cyclobutyl.
  • The N-(6-substituted-naphthalen-1-yl)methylene amide units are the core and together with the 4′-substituted-4-biphenyl units and amino units comprising a basic, nitrogen atom, make up the compounds of the present invention.
  • First Category of Core Units
  • The first category of the core units relates to core units having the formula:
    Figure US20080058423A1-20080306-C00022
    wherein R2 is hydrogen and each R8 unit is hydrogen. Compounds comprising Category I of the invention as described herein below contain a N-(6-substituted-naphthalen-1-yl)methylene unit as their core unit.
    Second Category of Core Units
  • The second category of the core units relates to core units having the formula:
    Figure US20080058423A1-20080306-C00023
    wherein R2 is methyl and each R8 unit is hydrogen. Compounds comprising Category II of the invention as described herein below contain a N-(6-substituted-naphthalen-1-yl)methylene unit as their core unit.
    Amino Units Comprising a Basic Nitrogen Atom
  • A third principal element of the MCH antagonists of the present invention relates to the R1 amino units comprising a basic nitrogen atom having the formula:
    -(L1)y-R4
    R4 has the formula:
    Figure US20080058423A1-20080306-C00024
    R6 and R7 are each independently chosen from:
    • i) hydrogen;
    • ii) C1-C8 substituted or unsubstituted linear, branched, or cyclic hydrocarbyl; for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, and the like;
    • iii) substituted or unsubstituted C6 or C10 aryl; or
      R6 and R7 can be taken together to form a substituted or unsubstituted heterocyclic ring having from 3 to 8 atoms; the index y is 0 or 1.
  • Aspect 1 of R1 units relates to units wherein R6 and R7 are each independently hydrogen or C1-C8 linear hydrocarbyl.
  • The first iteration of Aspect 1 relates to R6 and R7 are each independently chosen from hydrogen, methyl, and ethyl. This iteration includes amino units chosen from —NH2, —NH(CH3), —NH(CH2CH3), —N(CH3)2, —N(CH3)(CH2CH3), and —N(CH2CH3)2.
  • The second iteration of Aspect 1 relates to R6 and R7 are each independently chosen from hydrogen, propyl, isopropyl, n-butyl, and n-pentyl. This iteration includes amino units chosen from —NH(CH2CH2CH3), —N(CH2CH2CH3)2, —NH[CH2(CH3)2], —N[CH2(CH3)2]2, —NH(CH2CH2CH2CH3), —N(CH2CH2CH2CH3)2, and —N[(CH2)4CH3]2.
  • Aspect 2 of R1 units relates to units wherein R6 and R7 are taken together to form a heterocyclic ring having from 3 to 8 atoms. Non-limiting examples of rings which can be formed from R6 and R7 include: aziridin-1-yl, azetidin-1-yl, pyrrolidin-1-yl, 3-pyrrolin-1-yl, imidazolidin-1-yl, pyrazolidin-1-yl, piperidine-1-yl, piperazin-1-yl, 4-substituted-piperazin-1-yl, azepan-1-yl, and morpholin-4-yl.
  • Linking Units
  • L and L1 are linking units each of which is selected independently of the other. When the index x is equal to 0, L is absent; when x is equal to 1, L is present. When the index y is equal to 0, L1 is absent; when y is equal to 1, L1 is present.
  • L and L1 when present have the formula:
    Figure US20080058423A1-20080306-C00025
    wherein each R10 is independently chosen from:
    i) hydrogen;
    ii) C1-C6 substituted or unsubstituted linear, branched, or cyclic hydrocarbyl;
    iii) —CO2R9;
    iv) —CN;
    two R10 units on the same carbon are be taken together to form a carbonyl group; or R10 units from two adjacent linking units are taken together to form a double bond; R9 is hydrogen or C1-C4 linear, branched, or cyclic alkyl.
  • The index z indicates the number of L or L1 units which are present. The index z has the value form 1 to 3. For example, when an L or L1 unit is present and the index z for that unit is equal to 1, the L or L1 unit will have the formula:
    Figure US20080058423A1-20080306-C00026
    Likewise when the index z is equal to 2, the L or L1 unit which is present will have the formula:
    Figure US20080058423A1-20080306-C00027
  • Aspect 1 of linking units relates to compounds comprising L1 units (y=1) wherein L1 is a methylene unit which is formed when the index z=1 and each R10 unit is hydrogen. Taken together with the attached R4 unit, this combination provides R1 units having the formula:
    Figure US20080058423A1-20080306-C00028
  • Aspect 1 of linking units relates to both Category I and Category II compounds of the present invention having the formula:
    Figure US20080058423A1-20080306-C00029
    wherein L is absent (x=0) and L1 is a methylene unit.
  • Aspect 2 of linking units relates to compounds wherein L is a unit having the formula:
    Figure US20080058423A1-20080306-C00030
    and R10 is a unit selected from hydrogen, —CN, —CH3, or —NO2. A non-limiting example of an analog according to the present invention comprising the second aspect of linking units is 2-cyano-N-methyl-3-phenyl-N-(6-pyrrolidin-1-ylmethyl-naphthalen-1-ylmethyl)-acrylamide. The compounds of Aspect 2 also contain an L1 unit which is a methylene unit.
  • As it relates to nomenclature, the compounds of the present invention are 6-(amino unit comprising)-1-amidomethyl-naphthalenes having the general formula:
    Figure US20080058423A1-20080306-C00031
    wherein R comprises an aryl unit, R1 comprises a basic amino nitrogen, and R2 is hydrogen or a hydrocarbyl unit described herein below. The compounds of the present invention, as named herein, are given chemical names which are viewed as derivatives of the R unit carboxylic acid, for example, the compound having the formula:
    Figure US20080058423A1-20080306-C00032
    is named herein as N-(6-dimethylaminomethyl-naphthylen-1-ylmethyl)-4-fluorobenzamide and the compound having the formula:
    Figure US20080058423A1-20080306-C00033
    is named 4′-Fluoro-biphenyl-4-carboxylic acid (6-dimethylaminomethyl-naphthalen-1-ylmethyl)-amide. However, any exceptions to this naming scheme will be clear to the artisan of ordinary skill and not diminish from the description of the present invention.
    • Analog Categories
  • The analogs (compounds) of the present invention are arranged in several categories to assist the formulator in applying a rational synthetic strategy for the preparation of analogs which are not expressly exampled herein. The arrangement into categories does not imply increased or decreased efficacy or utility for any of the compositions of matter, compositions, or methods described herein.
  • Category I of the present invention relates to compounds with a core scaffold having the formula:
    Figure US20080058423A1-20080306-C00034
    wherein L is absent and the R3 unit is a substituted biphenyl thereby providing a core scaffold with the general formula:
    Figure US20080058423A1-20080306-C00035
    The first aspect of Category I relates to R4 units having the formula:
    Figure US20080058423A1-20080306-C00036
  • wherein R6 and R7 units each independently comprise hydrogen or C1-C8 substituted or unsubstituted linear or branched hydrocarbyl as further described herein below in Table I.
    TABLE I
    No. R3 R4
    1 4-biphenyl —NH2
    2 4-biphenyl —NHCH3
    3 4-biphenyl —N(CH3)2
    4 4-biphenyl —NH(C2H5)
    5 4-biphenyl —N(C2H5)2
    6 3′-fluoro-4-biphenyl —NH2
    7 3′-fluoro-4-biphenyl —NHCH3
    8 3′-fluoro-4-biphenyl —N(CH3)2
    9 3′-fluoro-4-biphenyl —NH(C2H5)
    10 3′-fluoro-4-biphenyl —N(C2H5)2
    11 3′-chloro-4-biphenyl —NH2
    12 3′-chloro-4-biphenyl —NHCH3
    13 3′-chloro-4-biphenyl —N(CH3)2
    14 3′-chloro-4-biphenyl —NH(C2H5)
    15 3′-chloro-4-biphenyl —N(C2H5)2
    16 3′-trifluoromethyl-4-biphenyl —NH2
    17 3′-trifluoromethyl-4-biphenyl —NHCH3
    18 3′-trifluoromethyl-4-biphenyl —N(CH3)2
    19 3′-trifluoromethyl-4-biphenyl —NH(C2H5)
    20 3′-trifluoromethyl-4-biphenyl —N(C2H5)2
    21 3′-cyano-4-biphenyl —NH2
    22 3′-cyano-4-biphenyl —NHCH3
    23 3′-cyano-4-biphenyl —N(CH3)2
    24 3′-cyano-4-biphenyl —NH(C2H5)
    25 3′-cyano-4-biphenyl —N(C2H5)2
    26 3′-nitro-4-biphenyl —NH2
    27 3′-nitro-4-biphenyl —NHCH3
    28 3′-nitro-4-biphenyl —N(CH3)2
    29 3′-nitro-4-biphenyl —NH(C2H5)
    30 3′-nitro-4-biphenyl —N(C2H5)2
    31 3′-methoxy-4-biphenyl —NH2
    32 3′-methoxy-4-biphenyl —NHCH3
    33 3′-methoxy-4-biphenyl —N(CH3)2
    34 3′-methoxy-4-biphenyl —NH(C2H5)
    35 3′-methoxy-4-biphenyl —N(C2H5)2
    36 4′-fluoro-4-biphenyl —NH2
    37 4′-fluoro-4-biphenyl —NHCH3
    38 4′-fluoro-4-biphenyl —N(CH3)2
    39 4′-fluoro-4-biphenyl —NH(C2H5)
    40 4′-fluoro-4-biphenyl —N(C2H5)2
    41 4′-chloro-4-biphenyl —NH2
    42 4′-chloro-4-biphenyl —NHCH3
    43 4′-chloro-4-biphenyl —N(CH3)2
    44 4′-chloro-4-biphenyl —NH(C2H5)
    45 4′-chloro-4-biphenyl —N(C2H5)2
    46 4′-trifluoromethyl-4-biphenyl —NH2
    47 4′-trifluoromethyl-4-biphenyl —NHCH3
    48 4′-trifluoromethyl-4-biphenyl —N(CH3)2
    49 4′-trifluoromethyl-4-biphenyl —NH(C2H5)
    50 4′-trifluoromethyl-4-biphenyl —N(C2H5)2
    51 4′-cyano-4-biphenyl —NH2
    52 4′-cyano-4-biphenyl —NHCH3
    53 4′-cyano-4-biphenyl —N(CH3)2
    54 4′-cyano-4-biphenyl —NH(C2H5)
    55 4′-cyano-4-biphenyl —N(C2H5)2
    56 4′-nitro-4-biphenyl —NH2
    57 4′-nitro-4-biphenyl —NHCH3
    58 4′-nitro-4-biphenyl —N(CH3)2
    59 4′-nitro-4-biphenyl —NH(C2H5)
    60 4′-nitro-4-biphenyl —N(C2H5)2
    61 4′-methoxy-4-biphenyl —NH2
    62 4′-methoxy-4-biphenyl —NHCH3
    63 4′-methoxy-4-biphenyl —N(CH3)2
    64 4′-methoxy-4-biphenyl —NH(C2H5)
    65 4′-methoxy-4-biphenyl —N(C2H5)2
  • The second aspect of Category I relates to compounds having a substituted biphenyl R3 unit providing a core scaffold with the general formula:
    Figure US20080058423A1-20080306-C00037
    wherein R4 unit have the formula:
    Figure US20080058423A1-20080306-C00038
  • R6 and R7 units are taken together to from a heterocyclic or heteroaryl ring having from 3 to 8 atoms as further described herein below in Table II.
    TABLE II
    No. R3 R4
    66 4-biphenyl aziridin-1-yl
    67 4-biphenyl pyrrolidin-1-yl
    68 4-biphenyl piperidin-1-yl
    69 4-biphenyl piperazin-1-yl
    70 4-biphenyl morpholin-4-yl
    71 4-biphenyl azepan-1-yl
    72 3′-fluoro-4-biphenyl aziridin-1-yl
    73 3′-fluoro-4-biphenyl pyrrolidin-1-yl
    74 3′-fluoro-4-biphenyl piperidin-1-yl
    75 3′-fluoro-4-biphenyl piperazin-1-yl
    76 3′-fluoro-4-biphenyl morpholin-4-yl
    77 3′-fluoro-4-biphenyl azepan-1-yl
    78 3′-chloro-4-biphenyl aziridin-1-yl
    79 3′-chloro-4-biphenyl pyrrolidin-1-yl
    80 3′-chloro-4-biphenyl piperidin-1-yl
    81 3′-chloro-4-biphenyl piperazin-1-yl
    82 3′-chloro-4-biphenyl morpholin-4-yl
    83 3′-chloro-4-biphenyl azepan-1-yl
    84 3′-trifluoromethyl-4-biphenyl aziridin-1-yl
    85 3′-trifluoromethyl-4-biphenyl pyrrolidin-1-yl
    86 3′-trifluoromethyl-4-biphenyl piperidin-1-yl
    87 3′-trifluoromethyl-4-biphenyl piperazin-1-yl
    88 3′-trifluoromethyl-4-biphenyl morpholin-4-yl
    89 3′-trifluoromethyl-4-biphenyl azepan-1-yl
    90 3′-cyano-4-biphenyl aziridin-1-yl
    91 3′-cyano-4-biphenyl pyrrolidin-1-yl
    92 3′-cyano-4-biphenyl piperidin-1-yl
    93 3′-cyano-4-biphenyl piperazin-1-yl
    94 3′-cyano-4-biphenyl morpholin-4-yl
    95 3′-cyano-4-biphenyl azepan-1-yl
    96 3′-nitro-4-biphenyl aziridin-1-yl
    97 3′-nitro-4-biphenyl pyrrolidin-1-yl
    98 3′-nitro-4-biphenyl piperidin-1-yl
    99 3′-nitro-4-biphenyl piperazin-1-yl
    100 3′-nitro-4-biphenyl morpholin-4-yl
    101 3′-nitro-4-biphenyl azepan-1-yl
    102 3′-methoxy-4-biphenyl aziridin-1-yl
    103 3′-methoxy-4-biphenyl pyrrolidin-1-yl
    104 3′-methoxy-4-biphenyl piperidin-1-yl
    105 3′-methoxy-4-biphenyl piperazin-1-yl
    106 3′-methoxy-4-biphenyl morpholin-4-yl
    107 3′-methoxy-4-biphenyl azepan-1-yl
    108 4′-fluoro-4-biphenyl aziridin-1-yl
    109 4′-fluoro-4-biphenyl pyrrolidin-1-yl
    110 4′-fluoro-4-biphenyl piperidin-1-yl
    111 4′-fluoro-4-biphenyl piperazin-1-yl
    112 4′-fluoro-4-biphenyl morpholin-4-yl
    113 4′-fluoro-4-biphenyl azepan-1-yl
    114 4′-chloro-4-biphenyl aziridin-1-yl
    115 4′-chloro-4-biphenyl pyrrolidin-1-yl
    116 4′-chloro-4-biphenyl piperidin-1-yl
    117 4′-chloro-4-biphenyl piperazin-1-yl
    118 4′-chloro-4-biphenyl morpholin-4-yl
    119 4′-chloro-4-biphenyl azepan-1-yl
    120 4′-trifluoromethyl-4-biphenyl aziridin-1-yl
    121 4′-trifluoromethyl-4-biphenyl pyrrolidin-1-yl
    122 4′-trifluoromethyl-4-biphenyl piperidin-1-yl
    123 4′-trifluoromethyl-4-biphenyl piperazin-1-yl
    124 4′-trifluoromethyl-4-biphenyl morpholin-4-yl
    125 4′-trifluoromethyl-4-biphenyl azepan-1-yl
    126 4′-cyano-4-biphenyl aziridin-1-yl
    127 4′-cyano-4-biphenyl pyrrolidin-1-yl
    128 4′-cyano-4-biphenyl piperidin-1-yl
    129 4′-cyano-4-biphenyl piperazin-1-yl
    130 4′-cyano-4-biphenyl morpholin-4-yl
    131 4′-cyano-4-biphenyl azepan-1-yl
    132 4′-nitro-4-biphenyl aziridin-1-yl
    133 4′-nitro-4-biphenyl pyrrolidin-1-yl
    134 4′-nitro-4-biphenyl piperidin-1-yl
    135 4′-nitro-4-biphenyl piperazin-1-yl
    136 4′-nitro-4-biphenyl morpholin-4-yl
    137 4′-nitro-4-biphenyl azepan-1-yl
    138 4′-methoxy-4-biphenyl aziridin-1-yl
    139 4′-methoxy-4-biphenyl pyrrolidin-1-yl
    140 4′-methoxy-4-biphenyl piperidin-1-yl
    141 4′-methoxy-4-biphenyl piperazin-1-yl
    142 4′-methoxy-4-biphenyl morpholin-4-yl
    143 4′-methoxy-4-biphenyl azepan-1-yl
  • The compounds which comprise the first and second aspect of Category I, wherein R2 is equal to hydrogen, can be prepared by the procedure described herein below and outlined in Scheme I. However, the artisan can substitute other procedures which facilitate the achievement of higher yields, purity, or which utilize readily available starting materials that can be introduced into the procedures outlined herein below. For example is step (c), for the formation of intermediate 3, the artisan can substitute a different reagent when preparing the acid chloride, inter alia, thionyl chloride.
  • As is relates to the variations in R4 for the first aspect of Category I compounds, in step (d) of Scheme I below, wherein intermediate 4 is prepared, the other aspects or iterations of this aspect of Category I can be prepared by the artisan substituting H3, NH2CH3, NH(CH2CH3)2, NH(CH3)(CH2CH3), NH2(CH2CH3), NH2[CH(CH3)2], and NH[CH(CH3)2]2, as well as other NHR6R7 amines wherein R6 and R7 are each independently C1-C8 substituted or unsubstituted linear or branched hydrocarbyl units, for NH(CH3)2 in step (d). However, the conditions may be necessarily adjusted by the formulator using practices standard and known to the skilled artisan.
  • As it relates to compounds encompassed by the second aspect of Category I, wherein R6 and R7 can be taken together to form a heterocyclic ring having from 3 to 8 atoms, aziridine, pyrrolidine, piperidine, piperazine, 1H-azepine, and morpholine, for example, these rings can be substituted for NH(CH3)2 in step (d) of Scheme I herein below. However, the conditions may be necessarily adjusted by the formulator using practices standard and known to the skilled artisan.
  • Likewise, 4′-fluoro-biphenyl-4-carbonyl chloride is replaced with 4′-chloro-biphenyl-4-carbonyl chloride, 4′-trifluoromethyl-biphenyl-4-carbonyl chloride, and the like to affect the full range of R units under Category I, first and second aspects.
    Figure US20080058423A1-20080306-C00039
    Figure US20080058423A1-20080306-C00040
    • EXAMPLE 1 4′-Fluoro-biphenyl-4-carboxylic acid (6-dimethylaminomethyl-naphthalen-1-ylmethyl)-amide (6)
  • Preparation of 5-bromo-naphthalene-2-carboxylic acid (1): To a boiling solution of 2-naphthoic acid (10.00 g, 58.14 mmol) in acetic acid (50 mL) is added dropwise bromine (3 mL) containing iodine (0.25 g). After the addition is complete, the solution is refluxed for 0.5 hr. A white precipitate forms during cooling and is isolated by filtration, washed with acetic acid and then water. The solid is triturated in methanol (100 mL) and 7.01 g (53.4% yield) of the desired product is obtained as a white solid. m.p. 248-250° C. 1H NMR (300 MHz, CD3OD): δ 8.94 (d, J=1.8 Hz, 1H), 8.52-8.42 (m, 3H), 8.27 (dd, J=1.8, 7.5 Hz, 1H), 7.79 (t, J=8.4 Hz, 1H).
  • Preparation of 5-cyano-naphthalene-2-carboxylic acid (2): A solution of Pd(OAc)2 (0.012 g, 0.054 mmol) and tri-o-tolylphosphine (0.073 g, 0.240 mmol) in degassed N-methylpyrrolidone (2 mL) is heated at 60° C. for 30 minutes. A solution of 1.0 M diethylzinc in hexane (0.11 mL, 0.11 mmol) is then added and stirring is continued for additional 30 minutes. To this mixture is added a mixture of 5-bromo-naphthalene-2-carboxylic acid, 1, (0.135 g, 0.536 mmol) and Zn(CN)2 (0.063 g, 0.536 mmol) in degassed N-methylpyrrolidone (2 mL). The resulting mixture is heated at 60° C. for 18 hrs. The reaction mixture is cooled and directly loaded to a prep-HPLC column eluting with CH3CN—H2O (0.1% TFA) to afford 0.085 g (80% yield) of the desired product as a white solid. m.p. 250° C. (dec.). 1H NMR (300 MHz, CDCl3): δ 8.61 (s, 1H), 8.18 (m, 2H), 8.14 (d, J=8.7 Hz, 1H), 7.94 (d, J=7.2 Hz, 1H), 7.54 (t, J=8.4 Hz, 1H). 13C NMR (75 MHz, CDCl3): δ 168.4, 134.9, 134.8, 134.5, 132.4, 131.9, 129.9, 128.5, 125.9, 125.5, 117.5, 110.2.
  • Preparation of 5-cyano-naphthalene-2-carboxylic acid chloride (3): To a suspension of 5-cyano-naphthalene-2-carboxylic acid, 2, (0.084 g, 0.426 mmol) in CH2Cl2 (2 mL) at room temperature containing 1 drop of DMF is added oxalyl chloride (0.074 mL). Once the solution is homogeneous, the solution is concentrated in vacuo and the crude product is used without further purification.
  • Preparation of 5-cyano-naphthalene-2-carboxylic acid dimethylamide (4): The crude product obtained above is dissolved in CH2Cl2 (2 mL) and 2.0 M Me2NH in THF (0.64 mL, 3.0 eq.) is added. The resulting solution is stirred at room temperature for 2 hours. The reaction mixture is washed with saturated NaHCO3, dried over anhydrous MgSO4 and evaporated to afford 0.095 g of the desired product as an off-white solid. The product is used for the next step without further purification. 1H NMR (300 MHz, CDCl3): δ 8.20 (d, J=9.0 Hz, 1H), 8.06 (d, J=8.4 Hz, 1H), 7.96 (s, 1H), 7.90 (d, J=7.2 Hz, 1H), 7.68 (dd, J=1.2, 9.0 Hz, 1H), 7.53 (t, J=8.1 Hz, 1H), 3.12 (s, 3H), 2.98 (s, 3H). 13C NMR (75 MHz, CDCl3): δ 170.7, 135.7, 133.9, 133.8, 132.6, 127.7, 127.3, 126.1, 125.7, 123.7, 117.7, 110.4, 39.8, 35.7.
  • Preparation of C-(6-dimethylaminomethyl-naphthalen-1-yl)-methylamine di-TFA salt (5): To a 0° C. solution of 5-cyano-naphthalene-2-carboxylic acid dimethylamide, 4, (0.095 g, 424 mmol) in anhydrous THF (5 mL) is added LAH (0.85 mL, 1M in THF, 2 eq.). After the addition is complete, the resulting solution is heated to 60° C. for 2 hours. The solution is cooled then the reaction quenched with 1N NaOH (several drops) and the white precipitate which forms is removed by filtration. The filtrate is concentrated in vacuo and the crude residue is purified by prep HPLC eluting with CH3CN:H2O (0.1% TFA) to afford 0.188 g of the desired product as the di-TFA salt. 1H NMR (300 MHz, CD3OD): δ 8.30 (d, J=9.0 Hz, 1H), 8.24 (d, J=1.8 Hz, 1H), 8.09 (d, J=7.8 Hz, 1H), 7.87 (dd, J=1.8, 8.7 Hz, 1H), 7.78 (d, J=6.6 Hz, 1H), 7.66 (d, J=8.4 Hz, 1H), 4.70 (s, 2H), 4.60, (s, 2H), 2.72 (s, 6H). LRMS: 214.98 (M+1), 169.89 (M+1-Me2NH).
  • Preparation of 4′-fluoro-biphenyl-4-carboxylic acid (6-dimethylaminomethyl-naphthalen-1-ylmethyl)-amide (6): A solution of C-(6-dimethylaminomethyl-naphthalen-1-yl)-methylamine di-TFA salt, 5, (0.180 g, 0.407 mmol), 4′-fluoro-biphenyl-4-carboxylic acid (0.088 g, 1 eq.), 1-hydroxybenzotriazole (0.066 g, 1.2 eq.), 1-(3-dimethylamino-propyl)-3-ethylcarbo-diimide (0.093 g, 1.2 eq.) and triethylamine (0.17 mL, 3 eq.) in DMF (5 mL) is stirred at room temperature for 2 hours. The reaction solution is concentrated in vacuo and then purified by prep HPLC eluting with CH3CN:H2O (0.1% TFA) to afford the desired product as the TFA salt which is treated with HCl to afford 50 mg (30% yield) of the desired product as the HCl salt in the form of a light yellow solid. 1H NMR (300 MHz, CD3OD): δ 8.39 (d, J=9.0 Hz, 1H), 8.12 (s, 1H), 8.01-7.95 (m, 3H), 7.76-7.58 (m, 8H), 7.23 (t, J=9.0 Hz, 1H), 5.14 (s, 2H), 4.54 (s, 2H), 2.94 (s, 6H). 13C NMR (75 MHz, CD3OD): δ 169.6, 165.2 (d, J=240 Hz), 163.5, 144.7, 137.5, 135.7, 135.1, 134.1, 133.2, 133.0, 130.1 (d, J=7.5 Hz), 129.5, 129.1, 128.6, 128.5, 128.0, 127.8, 126.2, 116.8 (d, J=22 Hz), 116.7, 62.3, 43.1, 42.5. 19F NMR (282 MHz, CD3OD): δ 45.8. Mass Spec.: Calcd.: 413.2029, found HRMS: 413.2019, Formula: C27H25FN2O+H, found LRMS: 413.27.
  • 4′-Trifluoromethyl-biphenyl-4-carboxylic acid (6-diethylaminomethyl-naphthalen-1-ylmethyl)-amide: 1H NMR (300 MHz, CD3OD): δ 8.24 (d, J=8.7 Hz, 1H), 8.15 (s, 1H), 8.03 (s, 1H), 7.93 (s, 1H), 7.77 (d, J=6.8 Hz, 1H), 7.72-7.67 (m, 8H), 7.62 (d, J=7.2 Hz, 1H), 4.66 (s, 2H), 4.58 (s, 2H), 3.51 (m, 4H), 2.08 (m, 6H). 13C NMR (75 MHz, CD3OD) δ 170.0, 166.4, 163.2, 146.3, 138.0, 135.6, 132.9, 131.8, 131.1, 130.7, 130.5, 130.4, 129.6, 128.3, 128.2, 128.2, 125.7, 117.3, 117.0, 59.5, 55.4, 41.5, 24.3. LRMS: 490.78 (M+1).
  • 4′-Fluoro-biphenyl-4-carboxylic acid (6-diethylaminomethyl-naphthalen-1-ylmethyl)-amide: 1H NMR (300 MHz, CD3OD): δ 8.22 (d, J=8.7 Hz, 1H), 8.14 (s, 1H), 7.95 (d, J=8.3 Hz, 1H), 7.87-7.75 (m, 4H), 7.64 (s, 1H), 7.61-7.48 (m, 6H), 4.57 (s, 2H), 4.47 (s, 2H), 3.19 (q, J=7.2 Hz, 4H), 1.27 (t, J=7.6 Hz, 6H). 13C NMR (75 MHz, CD3OD) δ 170.1, 164.3 (d, J=243 Hz), 146.2, 136.7, 135.5, 133.6, 133.0, 132.6, 131.7, 131.2, 130.9, 130.6 (d, J=8 Hz), 130.2, 129.5, 128.7, 128.4, 128.1, 125.7, 117.1 (d, J=22 Hz), 64.9, 57.4, 41.5, 9.5. LRMS: 453.3 (M+1).
  • 3′-Trifluoromethyl-biphenyl-4-carboxylic acid (6-diethylaminomethyl-naphthalen-1-ylmethyl)-amide: 1H NMR (300 MHz, CD3OD): δ 8.18 (d, J=8.7 Hz, 1H), 7.98 (s, 1H), 7.90-7.85 (m, 3H), 7.77-7.75 (m, 4H), 7.63-7.49 (m, 3H), 7.44-7.39 (m, 2H), 5.19 (s, 2H), 4.37 (s, 2H), 3.28 (q, J=7.1 Hz, 4H), 1.17 (t, J=7.1 Hz, 6H). 13C NMR (75 MHz, CD3OD) δ 170.9, 163.3, 144.3, 142.5, 136.0, 135.5, 133.4, 132.3, 131.5, 129.9, 129.8, 129.3, 128.8, 128.7, 128.6, 128.2, 126.4, 125.1, 120.5, 116.6, 112.7, 65.5, 57.60, 42.94, 9.44. LRMS: 490.8 (M+1).
  • Biphenyl-4-carboxylic acid (6-diethylaminomethyl-naphthalen-1-ylmethyl)-amide: 1H NMR (300 MHz, CD3OD): δ 8.35 (d, J=8.6 Hz, 1H), 8.10 (s, 1H), 7.95-7.91 (m, 3H), 7.73-7.69 (m, 2H), 7.67-7.63 (m, 4H), 7.58 (d, J=7.9 Hz, 1H), 7.48-7.43 (m, 2H), 7.38 (m, 1H), 5.10 (s, 2H), 4.51 (s, 2H), 3.24 (q, J=7.2 Hz, 4H), 1.35 (t, J=7.2 Hz, 6H). 13C NMR (75 MHz, CD3OD) δ 169.9, 146.2, 141.5, 136.1, 135.6, 134.5, 133.4, 133.3, 130.4, 129.8, 129.5, 129.4, 129.0, 128.9, 128.7, 128.5, 128.4, 128.2, 126.6, 63.2, 57.6, 42.9, 9.4. LRMS: 422.8 (M+1).
  • 4′-Fluoro-biphenyl-4-carboxylic acid (6-piperidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide: 1H NMR (300 MHz, CD3OD): δ 8.37 (d, J=8.8 Hz, 1H), 8.09 (s; 1H), 7.97 (m, 3H), 7.72-7.56 (m, 6H), 7.57 (d, J=7.8 Hz, 1H), 7.21 (t, J=8.8 Hz, 2H), 5.12 (s, 2H), 4.48 (s, 2H), 3.35 (m, 4H), 1.93 (m, 2H), 1.83-1.71 (m, 4H). 13C NMR (75 MHz, CD3OD) δ 166.4, 164.4 (d, J=246 Hz), 145.1, 137.9, 136.0, 135.5, 134.5, 133.7, 133.5, 130.5 (d, J=8 Hz), 130.4, 129.8, 129.5, 129.3, 128.9, 128.4, 128.1, 126.4, 117.1 (d, J=22 Hz), 62.12, 54.48, 42.94, 24.48, 23.10. LRMS: 503.3 (M+1); 453.3 (M+1).
  • 4′-Trifluoromethyl-biphenyl-4-carboxylic acid (6-piperidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide: 1H NMR (300 MHz, CD3OD): δ 8.36 (d, J=8.7 Hz, 1H), 8.09 (s, 1H), 8.01-7.97 (m, 2H), 7.92 (d, J=8.0 Hz, 1H), 7.89 (m, 2H), 7.82 (s, 1H), 7.79 (m, 2H), 7.76 (s, 1H), 7.69-7.67 (m, 2H), 7.60 (d, J=8.0 Hz, 1H), 5.15 (s, 2H), 4.48 (s, 2H), 3.30-3.10 (m, 4H), 1.95 (m, 6H). 13C NMR (75 MHz, CD3OD) δ 171.3, 165.3, 163.6, 146.8, 139.0, 136.1, 135.5, 133.7, 129.9, 129.6, 129.2, 128.8, 128.2, 127.3, 126.5, 126.1, 125.9, 116.7, 116.2, 62.2, 54.5, 42.9, 24.5, 23.1; LRMS: (M+1): 503.0.
  • 3′-Trifluoromethyl-biphenyl-4-carboxylic acid (6-piperidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide: 1H NMR (300 MHz, CD3OD): δ 8.25 (d, J=8.7 Hz, 1H), 8.02 (s, 1H), 7.95 (m, 2H), 7.84-7.78 (m, 3H), 7.64-7.57 (m, 6H), 7.48 (d, J=9.6 Hz, 1H), 5.03 (s, 2H), 4.37 (s, 2H), 3.10 (m, 4H), 1.91 (m, 6H). 13C NMR (75 MHz, CD3OD) δ 169.8, 144.2, 142.5, 136.0, 135.4, 133.7, 133.4, 132.2, 131.3, 130.4, 129.9, 129.7, 129.7, 129.5, 128.8, 128.6, 128.2, 128.1, 126.3, 125.0, 125.0, 62.0, 54.4, 45.8, 43.0, 24.4. LRMS: 502.8 (M+1).
  • Biphenyl-4-carboxylic acid (6-piperidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide: 1H NMR (300 MHz, CD3OD): δ 8.24 (d, J=8.7 Hz, 1H), 7.94 (s, 1H), 7.87-7.77 (m, 3H), 7.65-7.59 (m, 2H), 7.59-7.51 (m, 4H), 7.74 (d, J=8.0 Hz, 1H), 7.4-7.31 (m, 2H), 7.27 (d, J=7.2 Hz, 1H), 5.01 (s, 2H), 4.36 (s, 2H), 3.42 (m, 2H), 2.94 (m, 2H), 1.87-1.60 (m, 6H). 13C NMR (75 MHz, CD3OD) δ 170.1, 146.1, 141.4, 136.0, 135.5, 134.5, 133.7, 132.5, 130.4, 129.9, 129.5, 129.5, 129.0, 128.7, 128.5, 128.4, 128.2, 127.9, 126.5, 61.7, 54.5, 42.9, 24.5, 23.1. LRMS: 434.9 (M+1).
  • 4′-Trifluoromethyl-biphenyl-4-carboxylic acid (6-pyrrolidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide: 1H NMR (300 MHz, CD3OD): 1H NMR (300 MHz, CD3OD): δ 8.25 (d, J=8.7 Hz, 1H), 7.98 (s, 1H), 7.91-7.84 (m, 2H), 7.80 (d, J=8.1 Hz, 1H), 0.78-7.72 (m, 2H), 7.71-7.62 (m, 4H), 7.59-7.52 (m, 2H), 7.46 (d, J=8.0 Hz, 1H), 5.00 (s, 2H), 4.45 (s, 2H), 3.41 (m, 2H), 3.16 (m, 2H), 1.97 (m, 4H). 13C NMR (75 MHz, CD3OD) δ 169.9, 145.4, 144.4, 136.0, 135.6, 133.4, 132.7, 131.2, 130.3, 129.9, 129.6, 129.2, 128.9, 128.8, 128.7, 128.6, 128.1, 126.7, 126.6, 59.7, 55.4, 43.0, 24.2. LRMS: 489.33 (M+1).
  • 4′-Fluoro-biphenyl-4-carboxylic acid (6-pyrrolidin-1-ylmethyl-naphthalen-1-ylmethyl)-methyl-amide: 1H NMR (300 MHz, CD3OD): δ 8.23 (d, J=8.7 Hz, 1H), 7.97 (s, 1H), 7.87-7.76 (m, 3H), 7.63-7.52 (m, 6H), 7.45 (d, J=7.9 Hz, 1H), 7.14-7.03 (m, 2H), 4.99 (s, 2H), 4.44 (s, 2H), 3.40 (m, 2H), 3.15 (m, 2H), 2.15-1.90 (m, 4H). 13C NMR (75 MHz, CD3OD) δ 170.0, 164.8 (d, J=245 Hz), 145.1, 136.1, 135.6, 134.5, 133.4, 132.6, 130.5, 130.4 (d, J=8 Hz), 129.8, 129.5, 128.8, 128.6, 128.4, 128.1, 126.5, 117.3, 117.0 (d, J=22 Hz), 59.7, 55.4, 42.9, 24.2. LRMS: 439.35 (M+1).
  • 3′-Trifluoromethyl-biphenyl-4-carboxylic acid (6-pyrrolidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide: 1H NMR (300 MHz, CD3OD): δ 8.25 (d, J=8.6 Hz, 1H), 8.02 (s, 1H), 7.94 (m, 2H), 7.84-7.79 (m, 3H), 7.66-7.58 (m, 6H), 7.48 (d, J=7.6 Hz, 1H), 5.03 (s, 2H), 4.47 (s, 2H), 3.40-3.20 (m, 4H), 2.05 (m, 4H). 13C NMR (75 MHz, CD3OD) δ 170.0, 144.3, 142.5, 135.9, 135.5, 135.4, 133.3, 132.7, 132.2, 131.3, 129.9, 129.7, 128.7, 128.6, 128.1, 126.4, 126.1, 125.0, 125.0, 120.6, 116.4, 59.6, 55.2, 43.0, 24.2. LRMS: 489.37 (M+1).
  • Biphenyl-4-carboxylic acid (6-pyrrolidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide: 1H NMR (300 MHz, CD3OD): δ 8.11 (d, J=8.6 Hz, 1H), 7.88 (s, 1H), 7.81-7.76 (m, 2H), 7.71 (d, J=8.0 Hz, 1H), 7.55-7.42 (m, 6H), 7.35 (d, J=7.7 Hz, 1H), 7.29-7.16 (m, 3H), 4.90 (s, 2H), 4.32 (s, 2H), 3.31-3.10 (m, 4H), 1.92 (m, 4H). 13C NMR (75 MHz, CD3OD) δ 170.1, 146.0, 141.4, 136.0, 135.5, 134.5, 133.3, 132.6, 130.4, 129.8, 129.5, 129.5, 128.7, 128.6, 128.5, 128.4, 128.1, 127.9, 126.4, 59.6, 59.2, 42.9, 24.2. LRMS: 421.39 (M+1).
  • Other compounds which comprise the first aspect of Category I that are not specifically exemplified herein include the following:
    • 4′-Fluoro-biphenyl-4-carboxylic acid (6-aminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Chloro-biphenyl-4-carboxylic acid (6-aminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Trifluoromethyl-biphenyl-4-carboxylic acid (6-aminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Cyano-biphenyl-4-carboxylic acid (6-aminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Nitro-biphenyl-4-carboxylic acid (6-aminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methyl-biphenyl-4-carboxylic acid (6-aminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methoxy-biphenyl-4-carboxylic acid (6-aminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Chloro-biphenyl-4-carboxylic acid (6-dimethylaminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Trifluoromethyl-biphenyl-4-carboxylic acid (6-dimethylaminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Cyano-biphenyl-4-carboxylic acid (6-dimethylaminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Nitro-biphenyl-4-carboxylic acid (6-dimethylaminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methyl-biphenyl-4-carboxylic acid (6-dimethylaminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methoxy-biphenyl-4-carboxylic acid (6-dimethylaminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Chloro-biphenyl-4-carboxylic acid (6-diethylaminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Cyano-biphenyl-4-carboxylic acid (6-diethylaminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Nitro-biphenyl-4-carboxylic acid (6-diethylaminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methyl-biphenyl-4-carboxylic acid (6-diethylaminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methoxy-biphenyl-4-carboxylic acid (6-diethylaminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Fluoro-biphenyl-4-carboxylic acid (6-methylaminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Chloro-biphenyl-4-carboxylic acid (6-methylaminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Trifluoromethyl-biphenyl-4-carboxylic acid (6-methylaminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Cyano-biphenyl-4-carboxylic acid (6-methylaminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Nitro-biphenyl-4-carboxylic acid (6-methylaminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methyl-biphenyl-4-carboxylic acid (6-methylaminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methoxy-biphenyl-4-carboxylic acid (6-methylaminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Fluoro-biphenyl-4-carboxylic acid (6-ethylaminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Chloro-biphenyl-4-carboxylic acid (6-ethylaminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Trifluoromethyl-biphenyl-4-carboxylic acid (6-ethylaminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Cyano-biphenyl-4-carboxylic acid (6-ethylaminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Nitro-biphenyl-4-carboxylic acid (6-ethylaminomethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methyl-biphenyl-4-carboxylic acid (6-ethylaminomethyl-naphthalen-1-ylmethyl)-amide; and
    • 4′-Methoxy-biphenyl-4-carboxylic acid (6-ethylaminomethyl-naphthalen-1-ylmethyl)-amide.
  • Further compounds according to Category I wherein R6 and R7 are taken together to form a ring comprising 3 to 8 atoms:
    • 4′-Chloro-biphenyl-4-carboxylic acid (6-pyrrolidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Cyano-biphenyl-4-carboxylic acid (6-pyrrolidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Nitro-biphenyl-4-carboxylic acid (6-pyrrolidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methyl-biphenyl-4-carboxylic acid (6-pyrrolidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methoxy-biphenyl-4-carboxylic acid (6-pyrrolidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Chloro-biphenyl-4-carboxylic acid (6-piperidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Cyano-biphenyl-4-carboxylic acid (6-piperidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Nitro-biphenyl-4-carboxylic acid (6-piperidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methyl-biphenyl-4-carboxylic acid (6-piperidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methoxy-biphenyl-4-carboxylic acid (6-piperidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Fluoro-biphenyl-4-carboxylic acid (6-piperazin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Chloro-biphenyl-4-carboxylic acid (6-piperazin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Trifluoromethyl-biphenyl-4-carboxylic acid (6-piperazin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Cyano-biphenyl-4-carboxylic acid (6-piperazin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Nitro-biphenyl-4-carboxylic acid (6-piperazin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methyl-biphenyl-4-carboxylic acid (6-piperazin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methoxy-biphenyl-4-carboxylic acid (6-piperazin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Fluoro-biphenyl-4-carboxylic acid (6-aziridin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Chloro-biphenyl-4-carboxylic acid (6-aziridin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Trifluoromethyl-biphenyl-4-carboxylic acid (6-aziridin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Cyano-biphenyl-4-carboxylic acid (6-aziridin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Nitro-biphenyl-4-carboxylic acid (6-aziridin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methyl-biphenyl-4-carboxylic acid (6-aziridin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methoxy-biphenyl-4-carboxylic acid (6-aziridin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Fluoro-biphenyl-4-carboxylic acid (6-morpholin-4-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Chloro-biphenyl-4-carboxylic acid (6-morpholin-4-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Trifluoromethyl-biphenyl-4-carboxylic acid (6-morpholin-4-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Cyano-biphenyl-4-carboxylic acid (6-morpholin-4-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Nitro-biphenyl-4-carboxylic acid (6-morpholin-4-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methyl-biphenyl-4-carboxylic acid (6-morpholin-4-ylmethyl-naphthalen-1-ylmethyl)-amide; and
    • 4′-Methoxy-biphenyl-4-carboxylic acid (6-morpholin-4-ylmethyl-naphthalen-1-ylmethyl)-amide.
  • However, other compounds according to Category I of the present invention can be prepared by the method of Scheme I or by modifications made to Scheme I which are well understood by the artisan of ordinary skill.
  • Category II of the present invention relates to compounds with a core scaffold having the formula:
    Figure US20080058423A1-20080306-C00041
    and a substituted biphenyl R3 unit providing a core scaffold with the general formula:
    Figure US20080058423A1-20080306-C00042
    The first aspect of Category II relates to R4 units having the formula:
    Figure US20080058423A1-20080306-C00043
  • wherein R6 and R7 units each independently comprise hydrogen or C1-C8 substituted or unsubstituted linear or branched hydrocarbyl as further described herein below in Table III
    TABLE III
    No. R3 R4
    144 4-biphenyl —NH2
    145 4-biphenyl —NHCH3
    146 4-biphenyl —N(CH3)2
    147 4-biphenyl —NH(C2H5)
    148 4-biphenyl —N(C2H5)2
    149 3′-fluoro-4-biphenyl —NH2
    150 3′-fluoro-4-biphenyl —NHCH3
    151 3′-fluoro-4-biphenyl —N(CH3)2
    152 3′-fluoro-4-biphenyl —NH(C2H5)
    153 3′-fluoro-4-biphenyl —N(C2H5)2
    154 3′-chloro-4-biphenyl —NH2
    155 3′-chloro-4-biphenyl —NHCH3
    156 3′-chloro-4-biphenyl —N(CH3)2
    157 3′-chloro-4-biphenyl —NH(C2H5)
    158 3′-chloro-4-biphenyl —N(C2H5)2
    159 3′-trifluoromethyl-4-biphenyl —NH2
    160 3′-trifluoromethyl-4-biphenyl —NHCH3
    161 3′-trifluoromethyl-4-biphenyl —N(CH3)2
    162 3′-trifluoromethyl-4-biphenyl —NH(C2H5)
    163 3′-trifluoromethyl-4-biphenyl —N(C2H5)2
    164 3′-cyano-4-biphenyl —NH2
    165 3′-cyano-4-biphenyl —NHCH3
    166 3′-cyano-4-biphenyl —N(CH3)2
    167 3′-cyano-4-biphenyl —NH(C2H5)
    168 3′-cyano-4-biphenyl —N(C2H5)2
    169 3′-nitro-4-biphenyl —NH2
    170 3′-nitro-4-biphenyl —NHCH3
    171 3′-nitro-4-biphenyl —N(CH3)2
    172 3′-nitro-4-biphenyl —NH(C2H5)
    173 3′-nitro-4-biphenyl —N(C2H5)2
    174 3′-methoxy-4-biphenyl —NH2
    175 3′-methoxy-4-biphenyl —NHCH3
    176 3′-methoxy-4-biphenyl —N(CH3)2
    177 3′-methoxy-4-biphenyl —NH(C2H5)
    178 3′-methoxy-4-biphenyl —N(C2H5)2
    179 4′-fluoro-4-biphenyl —NH2
    180 4′-fluoro-4-biphenyl —NHCH3
    181 4′-fluoro-4-biphenyl —N(CH3)2
    182 4′-fluoro-4-biphenyl —NH(C2H5)
    183 4′-fluoro-4-biphenyl —N(C2H5)2
    184 4′-chloro-4-biphenyl —NH2
    185 4′-chloro-4-biphenyl —NHCH3
    186 4′-chloro-4-biphenyl —N(CH3)2
    187 4′-chloro-4-biphenyl —NH(C2H5)
    188 4′-chloro-4-biphenyl —N(C2H5)2
    189 4′-trifluoromethyl-4-biphenyl —NH2
    190 4′-trifluoromethyl-4-biphenyl —NHCH3
    191 4′-trifluoromethyl-4-biphenyl —N(CH3)2
    192 4′-trifluoromethyl-4-biphenyl —NH(C2H5)
    193 4′-trifluoromethyl-4-biphenyl —N(C2H5)2
    194 4′-cyano-4-biphenyl —NH2
    195 4′-cyano-4-biphenyl —NHCH3
    196 4′-cyano-4-biphenyl —N(CH3)2
    197 4′-cyano-4-biphenyl —NH(C2H5)
    198 4′-cyano-4-biphenyl —N(C2H5)2
    199 4′-nitro-4-biphenyl —NH2
    200 4′-nitro-4-biphenyl —NHCH3
    201 4′-nitro-4-biphenyl —N(CH3)2
    202 4′-nitro-4-biphenyl —NH(C2H5)
    203 4′-nitro-4-biphenyl —N(C2H5)2
    204 4′-methoxy-4-biphenyl —NH2
    205 4′-methoxy-4-biphenyl —NHCH3
    206 4′-methoxy-4-biphenyl —N(CH3)2
    207 4′-methoxy-4-biphenyl —NH(C2H5)
    208 4′-methoxy-4-biphenyl —N(C2H5)2
  • The second aspect of Category II relates to compounds having a substituted biphenyl R3 with the general formula:
    Figure US20080058423A1-20080306-C00044
    wherein R4 units have the formula:
    Figure US20080058423A1-20080306-C00045
  • R6 and R7 units are taken together to from a heterocyclic or heteroaryl ring having from 3 to 8 atoms as further described herein below in Table IV
    TABLE IV
    No. R3 R4
    209 4-biphenyl aziridin-1-yl
    210 4-biphenyl pyrrolidin-1-yl
    211 4-biphenyl piperidin-1-yl
    212 4-biphenyl piperazin-1-yl
    213 4-biphenyl morpholin-4-yl
    214 4-biphenyl azepan-1-yl
    215 3′-fluoro-4-biphenyl aziridin-1-yl
    216 3′-fluoro-4-biphenyl pyrrolidin-1-yl
    217 3′-fluoro-4-biphenyl piperidin-1-yl
    218 3′-fluoro-4-biphenyl piperazin-1-yl
    219 3′-fluoro-4-biphenyl morpholin-4-yl
    220 3′-fluoro-4-biphenyl azepan-1-yl
    221 3′-chloro-4-biphenyl aziridin-1-yl
    222 3′-chloro-4-biphenyl pyrrolidin-1-yl
    223 3′-chloro-4-biphenyl piperidin-1-yl
    224 3′-chloro-4-biphenyl piperazin-1-yl
    225 3′-chloro-4-biphenyl morpholin-4-yl
    226 3′-chloro-4-biphenyl azepan-1-yl
    227 3′-trifluoromethyl-4-biphenyl aziridin-1-yl
    228 3′-trifluoromethyl-4-biphenyl pyrrolidin-1-yl
    229 3′-trifluoromethyl-4-biphenyl piperidin-1-yl
    230 3′-trifluoromethyl-4-biphenyl piperazin-1-yl
    231 3′-trifluoromethyl-4-biphenyl morpholin-4-yl
    232 3′-trifluoromethyl-4-biphenyl azepan-1-yl
    233 3′-cyano-4-biphenyl aziridin-1-yl
    234 3′-cyano-4-biphenyl pyrrolidin-1-yl
    235 3′-cyano-4-biphenyl piperidin-1-yl
    236 3′-cyano-4-biphenyl piperazin-1-yl
    237 3′-cyano-4-biphenyl morpholin-4-yl
    238 3′cyano-4-biphenyl azepan-1-yl
    239 3′-nitro-4-biphenyl aziridin-1-yl
    240 3′-nitro-4-biphenyl pyrrolidin-1-yl
    241 3′-nitro-4-biphenyl piperidin-1-yl
    242 3′-nitro-4-biphenyl piperazin-1-yl
    243 3′-nitro-4-biphenyl morpholin-4-yl
    244 3′-nitro-4-biphenyl azepan-1-yl
    245 3′-methoxy-4-biphenyl aziridin-1-yl
    246 3′-methoxy-4-biphenyl pyrrolidin-1-yl
    247 3′-methoxy-4-biphenyl piperidin-1-yl
    248 3′-methoxy-4-biphenyl piperazin-1-yl
    249 3′-methoxy-4-biphenyl morpholin-4-yl
    250 3′-methoxy-4-biphenyl azepan-1-yl
    251 4′-fluoro-4-biphenyl aziridin-1-yl
    252 4′-fluoro-4-biphenyl pyrrolidin-1-yl
    253 4′-fluoro-4-biphenyl piperidin-1-yl
    254 4′-fluoro-4-biphenyl piperazin-1-yl
    255 4′-fluoro-4-biphenyl morpholin-4-yl
    256 4′-fluoro-4-biphenyl azepan-1-yl
    257 4′-chloro-4-biphenyl aziridin-1-yl
    258 4′-chloro-4-biphenyl pyrrolidin-1-yl
    259 4′-chloro-4-biphenyl piperidin-1-yl
    260 4′-chloro-4-biphenyl piperazin-1-yl
    261 4′-chloro-4-biphenyl morpholin-4-yl
    262 4′-chloro-4-biphenyl azepan-1-yl
    263 4′-trifluoromethyl-4-biphenyl aziridin-1-yl
    264 4′-trifluoromethyl-4-biphenyl pyrrolidin-1-yl
    265 4′-trifluoromethyl-4-biphenyl piperidin-1-yl
    266 4′-trifluoromethyl-4-biphenyl piperazin-1-yl
    267 4′-trifluoromethyl-4-biphenyl morpholin-4-yl
    268 4′-trifluoromethyl-4-biphenyl azepan-1-yl
    269 4′-cyano-4-biphenyl aziridin-1-yl
    270 4′-cyano-4-biphenyl pyrrolidin-1-yl
    271 4′-cyano-4-biphenyl piperidin-1-yl
    272 4′-cyano-4-biphenyl piperazin-1-yl
    273 4′-cyano-4-biphenyl morpholin-4-yl
    274 4′-cyano-4-biphenyl azepan-1-yl
    275 4′-nitro-4-biphenyl aziridin-1-yl
    276 4′-nitro-4-biphenyl pyrrolidin-1-yl
    277 4′-nitro-4-biphenyl piperidin-1-yl
    278 4′-nitro-4-biphenyl piperazin-1-yl
    279 4′-nitro-4-biphenyl morpholin-4-yl
    280 4′-cyano-4-biphenyl azepan-1-yl
    281 4′-methoxy-4-biphenyl aziridin-1-yl
    282 4′-methoxy-4-biphenyl pyrrolidin-1-yl
    283 4′-methoxy-4-biphenyl piperidin-1-yl
    284 4′-methoxy-4-biphenyl piperazin-1-yl
    285 4′-methoxy-4-biphenyl morpholin-4-yl
    286 4′-methoxy-4-biphenyl azepan-1-yl
  • The compounds which comprise the first and second aspect of Category II wherein R2 is equal to methyl, said compounds can be prepared by the procedure described herein below and outline in Scheme II. However, the artisan can substitute other procedures which facilitate the achievement of higher yields, purity, or which utilize readily available starting materials which can be introduced into the procedures outlined herein below. As is relates to the variations in R4 for the first aspect of Category II compounds, in step (d) Scheme I above intermediate 4 is prepared. Other aspects or iterations of this aspect of Category II can be achieved by the artisan substituting NH3, NH2CH3, NH(CH2CH3)2, NH(CH3)(CH2CH3), NH2(CH2CH3), NH2[CH(CH3)2], and NH[CH(CH3)2]2, as well as other NHR6R7 amines wherein R6 and R7 are each independently C1-C8 substituted or unsubstituted linear or branched hydrocarbyl units, for NH(CH3)2 in step (d). However, the conditions may be necessarily adjusted by the formulator using practices standard and known to the skilled artisan.
  • As it relates to compounds encompassed by the second aspect of Category II, wherein R6 and R7 can be taken together to form a heterocyclic ring having from 3 to 8 atoms, aziridine, pyrrolidine, piperidine, piperazine, 1H-azepine, and morpholine, for example, can be substituted for NH(CH3)2 in step (d) of Scheme I herein above. However, the conditions may be necessarily adjusted by the formulator using practices standard and known to the skilled artisan.
  • Likewise, 4′-trifluoromethyl-biphenyl-4-carbonyl chloride is replaced with 4′-fluoro-biphenyl-4-carbonyl chloride, 4′-chloro-biphenyl-4-carbonyl chloride, and the like to affect the full range of R units under Category II, first and second aspects.
    Figure US20080058423A1-20080306-C00046
    Figure US20080058423A1-20080306-C00047
    • EXAMPLE 2 4′-Trifluormethyl-biphenyl-4-carboxylic acid (6-dimethylaminomethyl-naphthalen-1-ylmethyl)-methyl-amide (10)
  • Preparation of 5-aminomethyl-naphthalene-2-carboxylic acid dimethylamide (7): A suspension of 5-cyano-naphthalene-2-carboxylic acid dimethylamide, 4, (18.93 g, 84.51 mmol), 28% NH4OH (24 mL) and EtOH (500 mL) is reacted with hydrogen (1 atmosphere) in the presence of Ra—Ni (8 g) catalyst for 4 days. The catalyst is removed by filtration and the filtrate is concentrated in vacuo to afford 18.66 g (97% yield) of the desired product. 1H NMR (300 MHz, CD3OD): δ 8.23 (d, J=8.7 Hz, 1H), 8.70-8.11 (m, 2H), 7.63-7.78 (m, 3H), 4.69 (s, 2H), 3.20, (s, 3H), 3.09 (s, 3H). LRMS: 228.99 (M+1), 211.96 (M+1-NH3).
  • Preparation of (6-dimethylcarbamoyl-naphthalen-1-ylmethyl)-carbamic acid tert-butyl ester (8): To a room temperature solution of 5-aminomethyl-naphthalene-2-carboxylic acid dimethylamide, 7, (18.66 g, 81.84 mmol) and di-tert-butyldicarbonate (17.84 g, 81.84 mmol) in CH2Cl2 (200 mL) is stirred at room temperature for 1 hour. The solution is concentrated in vacuo and the residue purified over silica (EtOAc/hexane 1:4 to 1:1) to afford 20.46 g (76% yields) of the desired product as a light yellow solid. 1H NMR (300 MHz, CDCl3): δ 8.04 (d, J=8.4 Hz, 1H), 7.92 (s, 1H), 7.85 (d, J=7.2 Hz, 1H), 7.42-7.58 (m, 3H), 4.91 (br, 1H), 4.78 (s, 2H), 4.78 (s, 2H), 3.11 (s, 6H), 1.48 (s, 9H). 13C NMR (75 MHz, CDCl3): δ 171.7, 156.8, 134.3, 133.9, 133.4, 131.7, 129.8, 127.8, 127.2, 126.5, 125.2, 124.0, 61.3, 43.1, 39.9, 35.7, 14.9. LRMS: 323.17 (M+Na), 301.17 (M+1).
  • Preparation of (6-dimethylaminomethyl-naphthalen-1-ylmethyl)-methyl-amine (9): To a room temperature solution of (6-dimethylcarbamoyl-naphthalen-1-ylmethyl)-carbamic acid tert-butyl ester, 8, (20.45 g, 62.4 mmol) in anhydrous THF (300 mL) is added 1 M LAH in THF (125 mL, 2 eq.). After the addition is complete the resulting solution is heated at reflux for 3 hours. The reaction solution is then cooled in an ice bath and quenched by the addition of water (2.7 mL). The resulting mixture is dried over MgSO4. The solid is removed by filtration and the filtrate concentrated in vacuo to afford 14.25 g of the desired product as a colorless oil. LRMS: 229.05 (M+1).
  • Preparation of 4′-trifluoromethyl-biphenyl-4-carboxylic acid (6-dimethylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide HCl (10): A solution of (6-dimethylamino-methyl-naphthalen-1-ylmethyl)-methyl-amine, 9, (14.25 g, 62.50 mmol), and 4′-trifluoromethyl-biphenyl-4-carbonyl chloride (17.81 g, 62.50 mmol) in CH2Cl2 (500 mL) is stirred at room temperature for 1 hr. The white solid which forms is collected by filtration and rinsed twice with CH2Cl2 (100 mL) to afford 22.0 g (69% yield) of the desired product as a white solid. 1H NMR (300 MHz, CD3OD): δ 8.37 (d, J=8.4 Hz, 1H), 8.15-7.56 (m, 13H), 5.31 (s, 2H), 5.31 and 5.14 (2×s, 2H, two rotamers), 3.17 and 2.93 (2×s, 9H, two rotamers). 13C NMR (75 MHz, CDCl3): δ 172.0, 165.5, 143.9, 141.4, 135.8, 134.1, 132.4, 132.1, 130.0, 129.0, 128.7, 127.7, 127.6, 127.4, 126.7, 126.6, 125.2, 123.9, 117.1, 61.1, 53.3, 42.1, 36.6. 19F NMR (282 MHz, CD3OD): δ 99.1. Mass Spec.: Calcd.: 477.5106, found HRMS: 477.5113, Formula: C29H27F3N2O+H, found LRMS: 477.27 (M+1).
  • The following are non-limiting examples of further compounds according to Category II of the present invention.
  • 4′-Fluoro-biphenyl-4-carboxylic acid (6-diethylaminomethyl-naphthalen-1-ylmethyl)-methyl-amide: 1H NMR (300 MHz, CD3OD): δ 7.03-8.38 (m, 14H), 5.27 (s, 2H), 4.56 (s, 2H), 3.10-3.40 (br, s, 4H), 2.90 (s, 3H), 1.41 (br, s, 6H); 13C NMR (75 MHz, CD3OD): δ 173.2, 164.1 (d, J=240 0 Hz) 143.0, 137.4, 135.8, 135.2, 133.2, 130.0 (d, J=8 Hz), 129.9, 129.3, 129.1, 128.6, 128.0, 127.7, 126.6, 126.0, 124.9, 116.9, 116.6 (d, J=22 Hz), 57.1, 49.0, 37.7, 34.6, 9.1; 19F NMR (282 MHz, CD3OD): δ 46.2. Mass Spec.: LRMS: 455.29 (M+H); Mass Spec.: LRMS: 455.29; HRMS: calcd.: 455.5863 for C30H31FN2O, found: 455.5845.
  • 3′-Trifluoromethyl-biphenyl-4-carboxylic acid (6-diethylaminomethyl-naphthalen-1-ylmethyl)-methyl-amide: 1H NMR (300 MHz, CD3OD): δ 8.39 (d, J=8.4 Hz, 1H), 8.12-8.27 (m, 2H), 7.55-8.03 (m, 11H), 5.31 (s, 2H), 4.57 (s, 2H), 3.10-3.40 (br, s, 4H), 2.93 (s, 3H), 1.41 (br, s, 6H); 13C NMR (75 MHz, CD3OD): δ 173.1, 142.3, 136.8, 135.9, 135.3, 134.4, 133.6, 133.2, 131.8, 131.3, 131.0, 129.6, 129.0, 128.9, 128.6, 128.4, 127.7, 126.2, 125.6, 124.6, 66.9, 57.2, 55.0, 37.6, 9.1; 19F NMR (282 MHz, CD3OD): δ 98.8; Mass Spec.: LRMS: 505.29; HRMS: calcd.: 505.5935 for C31H31F3N2O+H, found: 505.5935.
  • Biphenyl-4-carboxylic acid (6-diethylaminomethyl-naphthalen-1-ylmethyl)-methyl-amide: 1H NMR (300 MHz, CDCl3), δ 8.03 (br, s, 1H), 7.82 (m, 1H), 7.69-7.59 (m, 3H), 7.48-7.45 (m, 3H), 7.42-7.33 (m, 7H), 4.67 (s, 2H), 3.59 (s, 2H), 2.78 (s, 3H), 2.38 (d, J=7.5 Hz, 4H), 0.93 (t, J=7.5 Hz, 6H); 13C NMR (75 MHz, CDCl3) δ 164.29, 142.41, 135.98, 134.99, 134.62, 134.21, 133.74, 133.43, 132.96, 132.71, 129.4, 129.2, 128.91, 128.87, 128.17, 127.53, 127.41, 126.94, 101.07, 56.97, 48.90, 37.65, 34.59, 9.08; LRMS: 437.17 (M+H).
  • 4-Chloro-N-(6-diethylaminomethyl-naphthalen-1-ylmethyl)-N-methyl-benzamide: 1H NMR (300 MHz, CDCl3) δ 8.23 (br, s, 1H), 8.18-7.84 (m, 3H), 7.68-7.42 (m, 4H), 7.24 (m, 2H), 4.65 (s, 2H), 3.59 (s, 2H), 3.54 (s, 3H), 2.43 (d, J=7.5 Hz, 4H), 0.87 (t, J=7.5 Hz, 6H); LRMS: 394.93 (M+H).
  • N-(6-Diethylaminomethyl-naphthalen-1-ylmethyl)-4-fluoro-N-methyl-benzamide: 1H NMR (300 MHz, CDCl3) δ 8.22 (s, 1H), 8.20-7.87 (m, 3H), 7.66-7.41 (m, 4H), 7.23 (m, 2H), 4.69 (s, 2H), 3.59 (s, 2H), 3.57 (s, 3H), 2.44 (d, J=7.5 Hz, 4H), 0.88 (t, J=7.5 Hz, 6H); LRMS: 379.34 (M+H).
  • N-(6-Diethylaminomethyl-naphthalen-1-ylmethyl)-2-methoxy-N-methyl-benzamide: 1H NMR (300 MHz, CDCl3) δ 8.41 (d, J=6.7 Hz, 1H), 8.34 (m, 1H), 7.89 (m, 1H), 7.86 (m, 1H), 7.84 (m, 1H), 7.52 (m, 4H), 7.34 (t, J=9.6 Hz, 1H), 4.65 (s, 2H), 3.59 (s, 2H), 3.56 (s, 3H), 281 (s, 3H), 2.41 (d, J=7.4 Hz, 4H), 0.89 (t, J=7.5 Hz, 6H); LRMS: 391.23 (M+H).
  • N-(6-Diethylaminomethyl-naphthalen-1-ylmethyl)-N-methyl-4-nitro-benzamide: 1H NMR (300 MHz, CDCl3) δ 8.22 (s, 1H), 8.20-7.87 (m, 3H), 7.66-7.41 (m, 4H), 7.23 (m, 2H), 4.67 (s, 2H), 3.61 (s, 2H), 3.56 (s, 3H), 2.44 (d, J=7.5 Hz, 4H), 0.88 (t, J=7.5 Hz, 6H); LRMS: 406.21 (M+H).
  • N-(6-Diethylaminomethyl-naphthalen-1-ylmethyl)-4-fluoro-N-methyl-3-trifluoromethyl-benzamide: 1H NMR (300 MHz, CDCl3) δ 8.18 (d, J=7.6 Hz, 1H), 8.15 (d, J=8.4 Hz, 1H), 7.86 (d, J=8.2 Hz, 1H), 7.12 (t, J=8.4 Hz, 1H), 7.58 (s, 1H), 7.54 (s, 1H), 7.47 (d, J=8.4 Hz, 1H), 7.45 (d, J=8.4 Hz, 1H), 7.14 (d, J=8.2 Hz, 1H), 4.66 (s, 2H), 3.60 (s, 2H), 3.56 (s, 3H), 2.42 (d, J=7.5 Hz, 4H), 0.89 (t, J=7.5 Hz, 6H); LRMS: 447.23 (M+H).
  • 4′-Fluoro-biphenyl-4-carboxylic acid (6-piperidin-1-ylmethyl-naphthalen-1-ylmethyl)-methyl-amide: 1H NMR (300 MHz, CDCl3) δ 8.30-8.08 (m, 3H), 7.89 (s, 1H), 7.64-7.54 (m, 8H), 7.32-7.16 (m, 2H), 5.08 (br, s, 2H), 3.64 (s, 2H), 2.92 (s, 3H), 2.51 (br, s, 4H), 1.91 (br, s, 4H), 1.41 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 164.4, 161.45 (d, J=240 Hz), 142.3, 136.1, 134.9, 134.6, 134.1, 133.7, 133.4, 133.2, 132.6, 130.3 (d, J=8 Hz), 129.0, 127.9, 127.3, 126.8, 125.7, 124.9, 116.0 (d, J=22 Hz), 61.1, 53.3, 48.6, 30.1, 23.0, 22.2; LRMS: 467.63 (M+H).
  • Biphenyl-4-carboxylic acid methyl-(6-piperidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide: 1H NMR (300 MHz, CDCl3) δ 8.38 (d, J=8.2 Hz, 1H), 8.17 (s, 1H), 7.83-7.47 (m, 5H), 7.31-7.19 (m, 6H), 7.19 (m, 2H), 4.66 (s, 2H), 3.60 (s, 2H), 2.77 (s, 3H), 2.52 (br, s, 4H), 1.53 (br, s, 6H); 13C NMR (75 MHz, CDCl3) δ 164.4, 146.4, 142.4, 136.1, 134.9, 134.6, 134.2, 133.7, 133.5, 133.1, 132.7, 130.5, 129.2, 128.8, 128.1, 127.5, 127.4, 126.9, 100.2, 61.2, 53.3, 47.5, 30.0, 23.0, 22.2; LRMS: 449.34 (M+H) 471.63 (M+Na).
  • 2-(4′-Fluoro-biphenyl-4-yl)-N-methyl-N-(6-pyrrolidin-1-ylmethyl-naphthalen-1-ylmethyl)-acetamide: 1H NMR (300 MHz, CDCl3) δ 8.33 (d, J=8.2 Hz, 1H), 8.16 (s, 1H), 7.82-7.47 (m, 4H), 7.31-7.14 (m, 8H), 4.67 (s, 2H), 3.57 (s, 2H), 3.26 (s, 2H), 2.77 (s, 3H), 2.53 (br, s, 4H), 1.51 (br, s, 4H); 13C NMR (75 MHz, CDCl3) δ 163.7, 161.0 (d, J=240 Hz), 141.6, 136.2, 135.1, 134.6, 134.2, 133.7, 133.5, 133.2, 132.6, 129.3 (d, J=8 Hz), 129.0, 127.9, 127.3, 126.8, 125.7, 124.9, 116.1 (d, J=22 Hz), 68.6, 58.7, 53.6, 47.2, 32.6, 23.2; LRMS: 457.23 (M+H).
  • 4-Chloro-N-methyl-N-(6-pyrrolidin-1-ylmethyl-naphthalen-1-ylmethyl)-benzamide: 1H NMR (300 MHz, CDCl3) δ 8.29-8.24 (m, 2H), 8.17 (br, s, 1H), 8.14 (br, s, 1H), 7.67-7.59 (m, 4H), 7.55-7.47 (m, 2H), 4.77 (s, 2H), 3.65 (s, 2H), 2.77 (s, 3H), 2.53 (br, s, 4H), 1.51 (br, s, 4H); 13C NMR (75 MHz, CDCl3) δ 164.7, 158.3, 136.6, 135.2, 133.7, 128.8, 126.9, 126.6, 122.2, 117.5, 115.0, 114.7, 112.6, 111.7, 110.9, 56.7, 54.0, 49.3, 31.5, 23.0; LRMS: 394.2 (M+H).
  • 2-Methoxy-N-methyl-N-(6-pyrrolidin-1-ylmethyl-naphthalen-1-ylmethyl)-benzamide: 1H NMR (300 MHz, CDCl3) δ 8.22 (d, J=6.0 Hz, 1H), 7.89-7.80 (m, 2H), 7.64 (t, J=6.8 Hz, 1H), 7.58-7.45 (m, 3H), 7.29-7.08 (m, 3H), 4.78 (s, 2H), 3.93 (s, 3H), 3.68 (s, 2H), 2.76 (s, 3H), 2.55 (m, 4H), 1.53 (m, 4H); 13C NMR (75 MHz, CDCl3) δ 165.8, 158.1, 136.9, 135.2, 133.8, 128.8, 128.4, 128.0, 126.9, 126.7, 122.2, 117.5, 115.0, 114.7, 112.6, 111.7, 111.0, 56.7, 53.8, 51.3, 35.1, 31.5, 23.0; LRMS: 389.2 (M+H).
  • 4′-Trifluoromethyl-biphenyl-4-carboxylic acid methyl-(6-piperidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide: 1H NMR (300 MHz, CD3OD): δ 8.32 (d, J=8.2 Hz, 1H), 8.18 (m, 2H), 7.96 (m, 3H), 7.73-7.60 (m, 8H), 5.2 (s, 2H), 4.49 (s, 2H), 3.48 (m, 2H), 3.06 (m, 2H), 2.89 (s, 3H), 1.83 (m, 6H). 13C NMR (75 MHz, CD3OD) δ 173.47, 145.39, 142.79, 137.43, 135.62, 134.14, 133.99, 133.70, 131.42, 131.00, 130.57, 130.07, 129.32, 129.17, 128.98, 128.57, 128.16, 127.93, 127.34, 126.36, 62.18, 54.67, 38.30, 35.10, 24.56, 23.23. LRMS: 517.35 (M+1).
  • 3′-Trifluoromethyl-biphenyl-4-carboxylic acid methyl-(6-piperidin-1-ylmethyl-naphthalen-1-Ylmethyl)-amide: 1H NMR (300 MHz, CD3OD): δ 8.31 (s, 1H), 8.12 (s, 1H), 8.00-7.79 (m, 5H), 7.79-7.59 (m, 7H), 5.25 (s, 2H), 4.46 (s, 2H), 3.47 (m, 2H), 3.01 (m, 2H), 2.88 (s, 3H), 2.01-1.68 (m, 6H). 13C NMR (75 MHz, CD3OD) δ 173.5, 142.8, 142.6, 137.3, 135.6, 134.0, 133.7, 132.9, 132.5, 132.2, 131.4, 130.5, 130.2, 129.8, 129.2, 128.8, 128.5, 128.1, 127.8, 126.3, 126.0, 125.0, 62.0, 54.5, 38.1, 34.9, 24.5, 23.1. LRMS: 517.35 (M+1).
  • 4′-Trifluoromethyl-biphenyl-4-carboxylic acid (6-diethylaminomethyl-naphthalen-1-ylmethyl)-methyl-amide: 1H NMR (300 MHz, CD3OD): δ 8.27 (d, J=8.5 Hz, 1H), 8.02 (m, 2H), 7.91-7.80 (m, 3H), 7.76-7.60 (m, 6H), 7.46 (m, 2H), 5.2 (s, 2H), 4.45 (s, 2H), 3.28 (m, 4H), 2.81 (s, 3H), 1.31 (m, 6H). 13C NMR (75 MHz, CD3OD) δ 170.0, 163.4, 144.3, 142.6, 136.0, 135.5, 133.4, 132.4, 131.5, 129.9, 129.8, 129.3, 128.9, 128.7, 128.6, 128.2, 126.3, 125.0, 120.5, 116.6, 63.8, 57.6, 56.0, 42.9, 9.6. LRMS: 503.34 (M+1).
  • 3′-Trifluoromethyl-biphenyl-4-carboxylic acid (6-diethylaminomethyl-naphthalen-1-ylmethyl)-methyl-amide: 1H NMR (300 MHz, CD3OD): δ 8.24 (d, J=8.7 Hz, 1H), 8.04 (m, 2H), 7.93-7.81 (m, 3H), 7.77-7.59 (m, 6H), 7.43 (m, 2H), 5.20 (s, 2H), 4.45 (s, 2H), 3.27 (m, 4H), 2.80 (s, 3H), 1.29 (m, 6H). 13C NMR (75 MHz, CD3OD) δ. 170.3, 143.2, 142.5, 136.2, 135.6, 135.2, 133.4, 132.8, 132.2, 131.3, 130.1, 129.7, 129.5, 128.8, 128.6, 128.2, 126.6, 126.2, 125.9, 125.0, 120.7, 116.7, 64.3, 57.7, 55.9, 42.8, 9.7; LRMS: 503.38 (M+1).
  • 2-Cyano-N-methyl-3-phenyl-N-(6-pyrrolidin-1-ylmethyl-naphthalen-1-ylmethyl)-acrylamide: 1H NMR (300 MHz, CDCl3) δ 8.11 (br, s, 1H), 7.92 (d, J=6.0 Hz, 1H), 7.85-7.80 (m, 3H), 7.70-7.38 (m, 6H), 5.17 (s, 1H), 4.79 (s, 2H), 3.63 (s, 2H), 2.81 (s, 3H), 2.49 (br, s, 4H), 1.51 (br, s, 4H); 13C NMR (75 MHz, CDCl3) δ 165.6, 155.9, 152.6, 133.7, 132.7, 132.1, 132.3, 131.9, 131.8, 131.4, 130.4, 129.6, 129.4, 128.1, 126.8, 116.5, 112.8, 102.5, 58.7, 53.6, 47.3, 32.7, 23.3; LRMS: 410.28 (M+H).
  • Other compounds which comprise the first aspect of Category II that are not specifically exemplified herein include the following:
    • 4′-Fluoro-biphenyl-4-carboxylic acid (6-amino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Chloro-biphenyl-4-carboxylic acid (6-amino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Cyano-biphenyl-4-carboxylic acid (6-amino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Nitro-biphenyl-4-carboxylic acid (6-amino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Trifluoromethyl-biphenyl-4-carboxylic acid (6-amino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Methyl-biphenyl-4-carboxylic acid (6-amino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Methoxy-biphenyl-4-carboxylic acid (6-amino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Fluoro-biphenyl-4-carboxylic acid (6-dimethylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Chloro-biphenyl-4-carboxylic acid (6-dimethylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Cyano-biphenyl-4-carboxylic acid (6-dimethylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Nitro-biphenyl-4-carboxylic acid (6-dimethylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Methyl-biphenyl-4-carboxylic acid (6-dimethylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Methoxy-biphenyl-4-carboxylic acid (6-dimethylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Cyano-biphenyl-4-carboxylic acid (6-diethylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Methyl-biphenyl-4-carboxylic acid (6-diethylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Methoxy-biphenyl-4-carboxylic acid (6-diethylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Fluoro-biphenyl-4-carboxylic acid (6-methylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Chloro-biphenyl-4-carboxylic acid (6-methylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Cyano-biphenyl-4-carboxylic acid (6-methylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Nitro-biphenyl-4-carboxylic acid (6-methylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Trifluoromethyl-biphenyl-4-carboxylic acid (6-methylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Methyl-biphenyl-4-carboxylic acid (6-methylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Methoxy-biphenyl-4-carboxylic acid (6-methylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Fluoro-biphenyl-4-carboxylic acid (6-ethylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Chloro-biphenyl-4-carboxylic acid (6-ethylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Cyano-biphenyl-4-carboxylic acid (6-ethylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Nitro-biphenyl-4-carboxylic acid (6-ethylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Trifluoromethyl-biphenyl-4-carboxylic acid (6-ethylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Methyl-biphenyl-4-carboxylic acid (6-ethylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Methoxy-biphenyl-4-carboxylic acid (6-ethylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Fluoro-biphenyl-4-carboxylic acid (6-methylethylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Chloro-biphenyl-4-carboxylic acid (6-methylethylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Cyano-biphenyl-4-carboxylic acid (6-methylethylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Nitro-biphenyl-4-carboxylic acid (6-methylethylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Trifluoromethyl-biphenyl-4-carboxylic acid (6-methylethylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide;
    • 4′-Methyl-biphenyl-4-carboxylic acid (6-methylethylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide; and
    • 4′-Methoxy-biphenyl-4-carboxylic acid (6-methylethylamino-methyl-naphthalen-1-ylmethyl)-methyl-amide.
    • Further compounds according to Category I wherein R6 and R7 are taken together to form a ring comprising 3 to 8 atoms:
    • 4′-Fluoro-biphenyl-4-carboxylic acid methyl-(6-pyrrolidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Nitro-biphenyl-4-carboxylic acid methyl-(6-pyrrolidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Cyano-biphenyl-4-carboxylic acid methyl-(6-pyrrolidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Trifluoromethyl-biphenyl-4-carboxylic acid methyl-(6-pyrrolidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methyl-biphenyl-4-carboxylic acid methyl-(6-pyrrolidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methoxy-biphenyl-4-carboxylic acid methyl-(6-pyrrolidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Fluoro-biphenyl-4-carboxylic acid methyl-(6-piperidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Chloro-biphenyl-4-carboxylic acid methyl-(6-piperidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Nitro-biphenyl-4-carboxylic acid methyl-(6-piperidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Cyano-biphenyl-4-carboxylic acid methyl-(6-piperidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methyl-biphenyl-4-carboxylic acid methyl-(6-piperidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methoxy-biphenyl-4-carboxylic acid methyl-(6-piperidin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Fluoro-biphenyl-4-carboxylic acid methyl-(6-piperazin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Chloro-biphenyl-4-carboxylic acid methyl-(6-piperazin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Nitro-biphenyl-4-carboxylic acid methyl-(6-piperazin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Cyano-biphenyl-4-carboxylic acid methyl-(6-piperazin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Trifluoromethyl-biphenyl-4-carboxylic acid methyl-(6-piperazin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methyl-biphenyl-4-carboxylic acid methyl-(6-piperazin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methoxy-biphenyl-4-carboxylic acid methyl-(6-piperazin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Fluoro-biphenyl-4-carboxylic acid methyl-(6-aziridin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Chloro-biphenyl-4-carboxylic acid methyl-(6-aziridin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Nitro-biphenyl-4-carboxylic acid methyl-(6-aziridin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Cyano-biphenyl-4-carboxylic acid methyl-(6-aziridin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Trifluoromethyl-biphenyl-4-carboxylic acid methyl-(6-aziridin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methyl-biphenyl-4-carboxylic acid methyl-(6-aziridin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methoxy-biphenyl-4-carboxylic acid methyl-(6-aziridin-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Fluoro-biphenyl-4-carboxylic acid methyl-(6-morpholin-4-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Chloro-biphenyl-4-carboxylic acid methyl-(6-morpholin-4-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Nitro-biphenyl-4-carboxylic acid methyl-(6-morpholin-4-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Cyano-biphenyl-4-carboxylic acid methyl-(6-morpholin-4-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Trifluoromethyl-biphenyl-4-carboxylic acid methyl-(6-morpholin-4-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methyl-biphenyl-4-carboxylic acid methyl-(6-morpholin-4-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methoxy-biphenyl-4-carboxylic acid methyl-(6-morpholin-4-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Fluoro-biphenyl-4-carboxylic acid methyl-(6-azepan-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Chloro-biphenyl-4-carboxylic acid methyl-(6-azepan-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Nitro-biphenyl-4-carboxylic acid methyl-(6-azepan-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Cyano-biphenyl-4-carboxylic acid methyl-(6-azepan-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Trifluoromethyl-biphenyl-4-carboxylic acid methyl-(6-azepan-1-ylmethyl-naphthalen-1-ylmethyl)-amide;
    • 4′-Methyl-biphenyl-4-carboxylic acid methyl-(6-azepan-1-ylmethyl-naphthalen-1-ylmethyl)-amide; and
    • 4′-Methoxy-biphenyl-4-carboxylic acid methyl-(6-azepan-1-ylmethyl-naphthalen-1-ylmethyl)-amide.
    • However, other compounds according to Category II of the present invention can be prepared by the method of Scheme I or by modifications made to Scheme II which are well understood by the artisan of ordinary skill.
  • Compounds listed and described herein above have been found in many instances to exhibit activities (IC50 in the cell based assay described herein below or ones which are referenced herein) at a level below 1 micromolar (μM).
  • Each of the disease states or conditions which the formulator desires to treat may require differing levels or amounts of the compounds described herein to obtain a therapeutic level. The formulator can determine this amount by any of the common testing procedures known to the artisan.
    • Formulations
  • The present invention also relates to compositions or formulations which comprise the melanin concentrating hormone (MCH) antagonists according to the present invention. In general, the compositions of the present invention comprise:
      • a) an effective amount of one or more melanin concentrating hormone antagonists according to the present; and
      • b) one or more acceptable excipients.
  • For the purposes of the present invention the term “excipient” and “carrier” are used interchangeably throughout the description of the present invention and said terms are defined herein as, “ingredients which are used in the practice of formulating a safe and effective pharmaceutical composition.”
  • The formulator will understand that excipients are used primarily to serve in delivering a safe, stable, and functional pharmaceutical, serving not only as part of the overall vehicle for delivery but also as a means for achieving effective absorption by the recipient of the active ingredient. An excipient may fill a role as simple and direct as being an inert filler, or an excipient as used herein may be part of a pH stabilizing system or coating to insure delivery of the ingredients safely to the stomach. The formulator can also take advantage of the knowledge that selected compounds of the present invention have improved cellular potency, pharmacokinetic properties, as well as improved oral bioavailability.
  • Non-limiting examples of compositions according to the present invention include:
      • a) from about 0.1 mg to about 5000 mg of one or more melanin concentrating hormone antagonists according to the present invention; and
      • b) one or more excipient.
  • Another embodiment according to the present invention relates to the following composition:
      • a) from about 1 mg to about 1000 mg of one or more melanin concentrating hormone antagonists according to the present invention; and
      • b) one or more excipient.
  • A further embodiment according to the present invention relates to the following composition:
      • a) from about 10 mg to about 500 mg of one or more melanin concentrating hormone antagonists according to the present invention; and
      • b) one or more excipient.
  • A yet further embodiment according to the present invention relates to the following composition:
      • a) from about 100 mg to about 1000 mg of one or more melanin concentrating hormone antagonists according to the present invention; and
      • b) one or more excipient.
  • The term “effective amount” as used herein means “an amount of one or more melanin concentrating hormone antagonists, effective at dosages and for periods of time necessary to achieve the desired result.” An effective amount may vary according to factors known in the art, such as the disease state, age, sex, and weight of the human or animal and affinity of drug for target receptor being treated. Although particular dosage regimes may be described in examples herein, a person skilled in the art would appreciated that the dosage regime may be altered to provide optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. In addition, the compositions of the present invention can be administered as frequently as necessary to achieve a therapeutic amount.
  • Another aspect of the present invention relates to compositions which are anti-obesity compositions and therefore provide body weight control or maintenance of weight loss, the compositions of the present invention comprise:
      • a) an effective amount of one or more melanin concentrating hormone antagonists according to the present invention in an amount effective for providing body weight control or maintenance of weight loss;
      • b) one or more pharmaceutically acceptable excipients.
  • For the purposes of the present invention the term “body weight control or maintenance of weight loss” is defined herein as “the ability of a compound of the present invention to provide effective loss of body mass and to provide an effective maintenance of body mass at a particular body mass value (body weight).”
  • A second aspect of the present invention relates to compositions which are body weight gain controlling compositions and therefore provide weight gain control, the compositions of the present invention comprise:
      • a) an effective amount of one or more melanin concentrating hormone agonists according to the present invention in an amount effective for providing control of weight gain; and
      • b) one or more acceptable excipients.
  • A further aspect of the present invention relates to compositions which are anxiolytic and antidepressant compositions and therefore provide control of anxiety and/or relief from depression, the compositions of the present invention comprise:
      • a) an effective amount of one or more melanin concentrating hormone agonists according to the present invention in an amount effective for providing control of anxiety and/or relief from depression; and
      • b) one or more acceptable excipients.
  • The compositions of this invention are typically provided in unit dosage form. For the purposes of the present invention the term “unit dosage form” is defined herein as comprising an effective amount of one or more melanin concentrating hormone antagonists. The compositions of the present invention contain in one embodiment from about 0.1 mg to about 5000 mg of one or more melanin concentrating hormone antagonists, while in other embodiments the compositions comprise from about 10 mg to about 500 mg, or from about 100 mg to about 1000 mg respectively.
  • Non-limiting examples of substances which can serve as pharmaceutically-acceptable excipients or components thereof are sugars, inter alia, lactose, glucose and sucrose, sorbitol, mannitol; starches, inter alia, corn starch and potato starch; cellulose and its derivatives, inter alia, sodium carboxymethyl cellulose, ethyl cellulose, and methyl cellulose; powdered tragacanth; malt; gelatin; talc; solid lubricants, such as stearic acid and magnesium stearate; vegetable oils, propylene glycol, glycerin, and polyethylene glycol; agar; alginic acid; wetting agents and lubricants, inter alia, sodium lauryl sulfate; coloring agents; flavoring agents; tableting agents, stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic saline; and buffers.
  • Standard pharmaceutical formulation techniques are disclosed in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., latest edition and Peptide and Protein Drug Delivery, Marcel Dekker, NY, 1991. Dosage forms useful for making the compositions of the present invention or which are compatible with the methods of use as described herein below are described in the following references, all incorporated by reference herein: Modern Pharmaceutics, Chapters 9 and 10 (Banker & Rhodes, editors, 1979); Lieberman et al., Pharmaceutical Dosage Forms: Tablets (1981); and Ansel, Introduction to Pharmaceutical Dosage Forms 2d Edition (1976); Standard-Release Injectable Products, ed. J. Senior and M. Radomsk, Interpharm Press; Denver, Co. (2000).
    • Method of Use
  • Many human and mammalian disorders result from too much body mass (obesity or other over weight condition). Controlling body mass is a first step in preventing, as well as effectively treating many diseases and disease states. Among the disorders which are modulated, attenuated, abated, or otherwise controlled by the compounds of the present invention which serve as antagonists of MCH activity, is human obesity. This condition has been shown to be directly related to a wide range of disorders. The compounds of the present invention are capable of treating diseases by acting as antagonists of MCH activity with minimal, little, or no activity involving the 5-HT2c receptor.
  • As antagonists of MCH action upon the MCH receptor, the compounds of the present invention are useful in treating disorders that are mediated by MCH through the MCH receptor. Additional disorders other than obesity and food intake related illnesses that are mediated by MCH through the MCH receptor are thyroid hormone secretion, diuresis and water/electrolyte homeostasis, memory, sleep and arousal, anxiety and depression, seizure and in treatment of neurodegeneration or psychiatric disorders.
  • The compounds of the present invention have improved cellular potency and pharmacokinetic properties and this advantage is made use of by the fact the third aspect of the present invention as a whole, relates to a method for controlling obesity, and the subsequent weight management after weight loss. This is achieved by administering to a human or a higher mammal an effective amount of one or more of the compounds (analogs) as described herein.
  • Melanin Concentrating Hormone (MCH) activity, to which the antagonists of the present invention are directed, and as discussed herein above, is not limited to modulation of food intake as effects on the hypothalamic-pituitary axis have been reported.2
  • Further, as antagonists, it has been reported by Chaki et al.3 that antagonists of melanin concentrating hormone have shown significantly reduced immobility time in the forced swimming test in rats, indicating antidepressant-like effects. In addition this group has reported significantly reversed swim stress-induced anxiety in the elevated plus-maze test in rats and stress-induced hyperthermia in mice. These finding indicate that MCH antagonists have demonstrated anxiolytic and antidepressant activity.
  • Utilizing the melanin concentrating hormone (MCH) antagonists of the present invention will therefore affect a variety of diseases, disease states, conditions, or syndromes resulting from body weight disorders, inter alia, insulin resistance, glucose intolerance, Type-2 diabetes mellitus, coronary artery disease, elevated blood pressure, hypertension, dyslipidaemia, cancer (e.g., endometrial, cervical, ovarian, breast, prostate, gallbladder, colon), menstrual irregularities, hirsutism, infertility, gallbladder disease, restrictive lung disease, sleep apnea, gout, osteoarthritis, and thromboembolic disease.
    • 2. Critical Rev. in Neurobiol., Nahon, 8, 221-262 (1994).
    • 3. J. Pharmacol. Exp. Ther. 2005 May; 313(2):831-9.
  • Although the melanin concentrating hormone antagonists of the present invention are discrete chemical entities, the method of delivery or the method of use may be coupled with other suitable drug delivery systems. For example, a drug delivery technique useful for the compounds of the present invention is the conjugation of the compound to an active molecule capable of being transported through a biological barrier.4 A specific example constitutes the coupling of the compound of the invention to fragments of insulin to achieve transport across the blood brain barrier.5
    • 4. Zlokovic, B. V., Pharmaceutical Research, Vol. 12, pp. 1395-1406 (1995).
    • 5. Fukuta, M., et al. Pharmaceutical Res., Vol. 11, pp. 1681-1688 (1994).
      • For general reviews of technologies for drug delivery suitable for the compounds of the invention see:
  • The compounds of the present invention which are selective antagonists at the MCH-R1 receptor over the 5-HT2c receptor are suitable for use the following:
  • A method for controlling the body weight of humans and higher mammals, said method comprising administering to a human or higher mammal an effective amount of one or more selective antagonist of the present invention, including all enantiomeric and diasteriomeric forms and salts thereof.
  • A method for controlling weight gain in humans and higher mammals, said method comprising administering to a human or higher mammal an effective amount of one or more selective antagonist of the present invention, including all enantiomeric and diasteriomeric forms and salts thereof.
  • A method for controlling anxiety in humans and higher mammals, said method comprising administering to a human or higher mammal an effective amount of one or more selective antagonist of the present invention, including all enantiomeric and diasteriomeric forms and salts thereof.
  • A method for controlling depression in humans and higher mammals, said method comprising administering to a human or higher mammal an effective amount of one or more selective antagonist of the present invention, including all enantiomeric and diasteriomeric forms and salts thereof.
  • A method for controlling in humans one or more diseases, disease states, conditions, or syndromes relating to behavior, said diseases, disease states, conditions, or syndromes are chosen from anxiety and depression, memory impairment (including learning), muscle atrophy, and nerve growth and repair comprising administering an effective amount of one or more selective antagonist of the present invention, including all enantiomeric and diasteriomeric forms and salts thereof.
  • A method for controlling in humans one or more diseases, disease states, conditions, or syndromes resulting from body weight disorders, said diseases, disease states, conditions, or syndromes are chosen from insulin resistance, glucose intolerance, Type-2 diabetes mellitus, coronary artery disease, elevated blood pressure, hypertension, dyslipidaemia, menstrual irregularities, hirsutism, gallbladder disease, restrictive lung disease, sleep apnea, gout, osteoarthritis, and thromboembolic disease, said method comprising administering to a human an effective amount of one or more selective antagonist of the present invention, including all enantiomeric and diasteriomeric forms and salts thereof.
    • Procedures Binding and Functional Assays for Melanin Concentrating Hormone (MCH)
  • In vitro binding and function assays are performed on membranes derived from cells or tissues expressing endogenous MCH1R. Competition binding assays are performed to identify high affinity compounds. Briefly, either radiolabeled or europium labeled MCH with varying concentrations of competitor compound which are incubated with membranes expressing the receptor. Rat brain membrane or cell lines, including but not limited to human Kelly neuroblastoma cells, A-431 epidermoid cells, and rat PC-12 cells are known to express endogenous MCH1R and are used in the assay. Binding is allowed to proceed until equilibrium is reached then bound labeled MCH is separated from free MCH by capturing membranes onto a filter. The filters are washed to remove loosely associated MCH and labeled MCH is quantified. Data is analyzed and IC50 and Ki are calculated to determine compound affinity.
  • MCH function assays are performed in an analogous manner to the binding assay. Competition assays are performed with a single concentration of MCH and varying concentrations of compound. Function is assayed using GTP binding or a functional response (e.g. Calcium uptake, MAP/ERK activation) because the MCH1R is a G-protein coupled receptor that couples the Gi/o, and Gq proteins and has been shown to elicit these cellular functional responses. The assay can be performed on the same membranes as used for the binding assays. There are readily available kits for measuring GTP binding to membranes (e.g. Perkin Elmer Life Sciences). Data is analyzed and IC50 values are generated to determine whether the compound is an agonist or antagonist.
    • Binding Assays for Serotonin Receptor, 5-HT2c Receptor
  • MCH antagonist compounds are evaluated for binding to the serotonin 5-HT2c receptor to determine receptor selectivity. Binding activity is assessed using a competitive assay with 3H-mesulergine (Perkin Elmer), a 5-HT2c selective ligand, on membrane containing the 5-HT2c receptor. Briefly, 1 nM 3H-mesulergine and varying concentrations of the compound are incubated with 5-HT2c receptor membranes, following an incubation period, the membranes are washed and 3H-mesulergine bound to membranes is measured in a liquid scintillation counter. The amount of bound 3H-mesulergine at the varying concentration of competitor compound is used to derive the affinity (Ki) of the compound for the 5-HT2c receptor. 5-HT2c receptor containing membranes are readily available from several companies including Perkin-Elmer and Euroscreen.
  • The following table shows IC50 (nM) binding data for selected compounds at both the MCH1R and 5-HT2c receptors.
    TABLE V
    Compound MCH1R 5-HT2C
    4′-Fluoro-biphenyl-4-carboxylic acid 12 1125
    (6-dimethylaminomethyl-naphthalen-1-
    ylmethyl)-amide
    4′-Trifluoromethyl-biphenyl-4- 70 2058
    carboxylic acid (6-diethylaminomethyl-
    naphthalen-1-ylmethyl)-methyl-amide
    • Receptor Ligand Selectivity
  • The compounds of the present invention will interact preferentially (i.e., selectively) with MCH-1R relative to 5-HT2c receptors. Selectivity is particularly important when the compounds are administered to humans or other animals, to minimize the number of side effects associated with their administration. For example, MCH-1R selectivity of a compound relative to 5-HT2c is defined herein as the ratio of the EC50 of the compound for an MCH-1R receptor (“MCH-1R-EC50”) over the EC50 of the compound for the 5-HT2c (5-HT2c-EC50) receptor, the EC50 values being measured as described above. The formulas are as follows:
    MCH-1R/5-HT 2c selectivity=[MCH-1R-EC 50]/[5-HT 2c-EC 50]
  • For the purposes of the present invention a “selective binding” is binding to the MCH-R1 receptor at a level at least about 10 fold greater than at the 5-HT2c receptor. For example, a compound with an IC-50 at MCH-R1 of 12 nM and an IC-50 at 5-HT2c of 1125 nM would be a compound which is a selective antagonist at the MCH-R1 receptor over the 5-HT2c receptor. In other treatments, methods, or compositions this value is at least about 100, while for yet other embodiments of the present invention the selectivity is at least about 1000.
  • All documents cited are, in relevant part, incorporated herein by reference; the citation of any document is not to be construed as an admission that it is prior art with respect to the present invention.
  • While particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.

Claims (8)

1.-14. (canceled)
15. A method for controlling obesity in humans and higher mammals, said method comprising the step of administering to a human or higher mammal an effective amount of one or more compounds, according to claim 1.
16. A method for controlling weight gain in humans and higher mammals, said method comprising administering to a human or higher mammal an effective amount of one or more compounds according to claim 1.
17. A method for controlling the body weight of humans and higher mammals, said method comprising administering to a human or higher mammal an effective amount of one or more compounds according to claim 1.
18. A method for controlling anxiety in humans and higher mammals, said method comprising administering to a human or higher mammal an effective amount of one or more compounds according to claim 1.
19. A method for controlling depression in humans and higher mammals, said method comprising administering to a human or higher mammal an effective amount of one or more compounds according to claim 1.
20. A method for controlling in humans one or more diseases, disease states, conditions, or syndromes relating to behavior, said diseases, disease states, conditions, or syndromes are chosen from memory impairment (including learning), cardiovascular function, inflammation, sepsis, cardiogenic and hypovolemic shock, sexual dysfunction, penile erection, muscle atrophy, nerve growth and repair, and intrauterine fetal growth, said method comprising administering to a human an effective amount of one or more compounds according to claim 1.
21. A method for controlling in humans one or more diseases, disease states, conditions, or syndromes resulting from body weight disorders, said diseases, disease states, conditions, or syndromes are chosen from insulin resistance, glucose intolerance, Type-2 diabetes mellitus, coronary artery disease, elevated blood pressure, hypertension, dyslipidaemia, endometrial cancer, cervical cancer, ovarian cancer, breast cancer, prostate cancer, gallbladder cancer, colon cancer, menstrual irregularities, hirsutism, infertility, gallbladder disease, restrictive lung disease, sleep apnea, gout, osteoarthritis, and thromboembolic disease, said method comprising administering to a human an effective amount of one or more compounds according to claim 1.
US11/978,434 2004-07-15 2007-10-29 Melanin concentrating hormone antagonists Abandoned US20080058423A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/978,434 US20080058423A1 (en) 2004-07-15 2007-10-29 Melanin concentrating hormone antagonists

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58820904P 2004-07-15 2004-07-15
US11/180,814 US7368462B1 (en) 2004-07-15 2005-07-13 Melanin concentrating hormone antagonists
US11/978,434 US20080058423A1 (en) 2004-07-15 2007-10-29 Melanin concentrating hormone antagonists

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/180,814 Division US7368462B1 (en) 2004-07-15 2005-07-13 Melanin concentrating hormone antagonists

Publications (1)

Publication Number Publication Date
US20080058423A1 true US20080058423A1 (en) 2008-03-06

Family

ID=39332329

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/180,814 Expired - Fee Related US7368462B1 (en) 2004-07-15 2005-07-13 Melanin concentrating hormone antagonists
US11/978,434 Abandoned US20080058423A1 (en) 2004-07-15 2007-10-29 Melanin concentrating hormone antagonists

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/180,814 Expired - Fee Related US7368462B1 (en) 2004-07-15 2005-07-13 Melanin concentrating hormone antagonists

Country Status (1)

Country Link
US (2) US7368462B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8552199B2 (en) 2009-02-13 2013-10-08 Sanofi Substituted indanes, method for the production thereof, and use thereof as drugs
US8841290B2 (en) 2009-02-13 2014-09-23 Sanofi Substituted tetrahydronaphthalenes, method for the production thereof, and use thereof as drugs

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8552199B2 (en) 2009-02-13 2013-10-08 Sanofi Substituted indanes, method for the production thereof, and use thereof as drugs
US8841290B2 (en) 2009-02-13 2014-09-23 Sanofi Substituted tetrahydronaphthalenes, method for the production thereof, and use thereof as drugs

Also Published As

Publication number Publication date
US7368462B1 (en) 2008-05-06

Similar Documents

Publication Publication Date Title
EP2208727B1 (en) Diaryl ethers as opioid receptor antagonist
US8338611B2 (en) Opioid receptor antagonists
EP1697307B1 (en) Opioid receptor antagonists
US20100278835A1 (en) Novel compounds 660
DE69418601T2 (en) GUANID DERIVATIVES WITH THERAPEUTIC EFFECT
US20080200524A1 (en) Amide compounds as ion channel ligands and uses thereof
US20080312237A1 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
US8273733B2 (en) Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics
US20050059823A1 (en) Fused ring heterocycles as potassium channel modulators
US20110136877A1 (en) 2-phenyl phenoxyacetic acids useful for treating inflammatory disorders
EP1976851A2 (en) Phenoxy-substituted pyrimidines as adenosine receptor antagonists
EP1699783B1 (en) Opioid receptor antagonists
EP0113778A1 (en) Aryl substituted aminomethyl benzene derivatives useful as antiarrhythmic agents.
PT1720544E (en) Novel azabicyclic derivatives, preparation method thereof and pharmaceutical compositions containing same
DE69511260T2 (en) BICYCLIC AMIDINE DERIVATIVES AS NO-SYNTHETASE INHIBITORS
US6569880B2 (en) Bis(benzimidazole) derivatives serving as potassium blocking agents
KR20150052419A (en) Biguanide compounds and use thereof
CZ278198A3 (en) 2-(arylphenyl)aminoimidazoline derivatives
US7288543B2 (en) Opioid receptor antagonists
US20080058423A1 (en) Melanin concentrating hormone antagonists
US7304065B2 (en) Melanin concentrating hormone antagonists
EP0585116B1 (en) 1-Alkoxy-naphthalene-2-carboxamide derivatives with high affinity for the serotonin 5-HT1A receptor
US20060247239A1 (en) Melanin concentrating hormone antagonists
CN116283668A (en) Diaryl ureas as CB1 allosteric modulators
KR100843352B1 (en) 1,2-dihydro-1-oxophthalazinyl piperazine compound having activity as an antagonist of serotonin receptor 5-HT2a or 5-HT2c, and preparation method thereof

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载